Compositions and methods of treating vascular diseases
A novel method for producing vascular progenitor cells addresses the limitations of current vascular disease treatments by enhancing tube formation and angiogenesis, offering a safer and more effective treatment for conditions like cardiovascular disease and pulmonary hypertension.
Patent Information
- Application Number
- PCT/US2026/026677
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for vascular diseases, such as cardiovascular disease, pulmonary hypertension, and peripheral arterial disease, are limited and often invasive, lacking effective methods to prevent pathogenic remodeling and have significant side effects.
A novel method for producing vascular progenitor cells (VPCs) through in vitro differentiation of pluripotent stem cells using specific culture conditions and additives, resulting in a more mature and enriched cell population with improved efficacy in stabilizing tube formation and promoting angiogenesis.
The produced VPCs exhibit enhanced stability and angiogenic properties, providing a safer and more effective treatment for vascular diseases by increasing blood flow, collateralization, and promoting wound healing.
Smart Images

Figure IMGF000020_0001 
Figure IMGF000024_0001 
Figure IMGF000044_0001_TABLE
Abstract
Description
127206-11520COMPOSITIONS AND METHODS OF TREATING VASCULAR DISEASESRELATED APPLICATION
[0001] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 800,553, filed on May 6, 2025, the entire contents of which are incorporated herein by reference.FIELD OF THE INVENTION
[0002] The present invention relates to novel vascular progenitor cells (VPCs) obtained by in vitro differentiation of pluripotent stem cells, and methods for producing the VPCs. The present invention also relates to methods for treating vascular diseases using the VPCs.BACKGROUND
[0003] Vascular diseases are conditions that affect the body’s network of blood vessels, which range from diseases of arteries, veins and lymph vessels to blood disorders that affect circulation. The most common vascular diseases are cardiovascular disease, peripheral artery disease, abdominal aortic aneurysm, carotid artery disease, arteriovenous malformation, critical limb ischemia, pulmonary embolism (blood clots), deep vein thrombosis, chronic venous insufficiency, and varicose veins.
[0004] Cardiovascular disease is a class of diseases that involves the heart or blood vessels and is the leading cause of death worldwide. In the United States alone, approximately 84 million people suffer from cardiovascular disease, and almost one out of every three deaths results from cardiovascular disease.
[0005] Pulmonary hypertension (PH) is a condition characterized by increased pressure in the main pulmonary artery. A deadly form of PH is pulmonary arterial hypertension (PAH) and typically leads to death within an average of 2.8 years from diagnosis. PAH is characterized by vasoconstriction and remodeling of the pulmonary vessels. Standard available therapies may improve the quality of life and prognosis of patients but typically do not directly prevent the pathogenic remodeling process and may sometimes have serious side effects.
[0006] Peripheral arterial disease (PAD) is an abnormal narrowing and obstruction of the arteries other than those of the cerebral and coronary circulations. Critical limb ischemia (CLI) is a serious form of PAD that results in severe blockage in the arteries of the lower1MEI 52993232v.l127206-11520extremities. CLI is associated with major limb loss, myocardial infarction, stroke, and death. To date, there is no effective treatment for CLI.
[0007] Coronary artery disease is the most common form of cardiovascular disease and is caused by reduced blood flow and oxygen to the heart muscle due to atherosclerosis of the arteries of the heart. Patients with coronary artery disease often receive balloon angioplasty or stents to clear occluded arteries. Some undergo coronary artery bypass surgery at high expense and risk.
[0008] Treatment for vascular diseases is limited. While most of the treatment methods involve invasive surgical procedures, the others focus on the prevention of progression of existing conditions. Accordingly, there is still a need in the art for improved treatments for vascular diseases.SUMMARY OF THE INVENTION
[0009] The present disclosure provides a novel method for producing vascular progenitor cells (VPCs), which generates VPCs with unique phenotypes and improved efficacy in stabilizing tube formation of human endothelial cells in vitro and promoting angiogenesis and vasculogenesis in vivo.
[0010] In comparison with previous methods for VPC generation, the methods described herein utilize different medium and additives and include additional steps, such as, harvesting, freezing, thawing, and / or replating intermediate VPCs. The methods disclosed herein result in production of a more effective, safer, scalable, regulatory authority compliant population of novel VPCs. In particular, these novel VPCs represent a more mature and enriched cell population with only two distinct subpopulations, endothelial cells and perivascular / mesenchymal stem cell (MSC)-like cells, thus having a better safety profile, while VPCs generated from previous methods have five to six subpopulations. Notably, the endothelial population of VPCs exhibit a more matured phenotype. Advantageously, VPCs produced by the methods disclosed herein show improved efficacy in stabilizing tube formation of human endothelial cells in vitro and promoting angiogenesis in a diabetic mouse model, in comparison with VPCs produced by previous methods.
[0011] Accordingly, the present invention provides methods of producing a population of vascular progenitor cells (VPCs) by in vitro differentiation of pluripotent stem cells, wherein the method comprises (a) culturing the pluripotent stem cells on an extracellular matrix surface in a pluripotent stem cell expansion medium, (b) culturing the pluripotent stem cells2MEI 52993232v.l127206-11520from step (a) on an extracellular matrix surface in a VPC differentiation medium comprising vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and bone morphogenetic protein 4 (BMP4) for about 6 days to produce a population of intermediate VPCs, (c) harvesting the population of intermediate VPCs from step (b); and (d) replating the population of intermediate VPCs from step (c) on an extracellular matrix surface in an endothelial expansion medium for about 4 or more days, thereby producing the population of VPCs.
[0012] In some embodiments, the extracellular matrix surface is a collagen-IV-coated surface. In some embodiments, the extracellular matrix surface is a human collagen-IV-coated surface.
[0013] In some embodiments, the pluripotent stem cells are human embryonic stem cells, or human induced pluripotent stem cells.
[0014] In some embodiments, the pluripotent stem cell expansion medium comprises a Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor. In some embodiments, the pluripotent stem cell expansion medium comprises about 5-20 pM ROCK inhibitor. In some embodiments, the pluripotent stem cell expansion medium comprises about 10 M ROCK inhibitor. In some embodiments, the ROCK inhibitor is Y27632.
[0015] In some embodiments, the VPC differentiation medium comprises about 5-50 ng / mL VEGF, about 5-50 ng / mL FGF, and about 5-25 ng / mL BMP4. In some embodiments, the VPC differentiation medium comprises about 50 ng / mL VEGF, about 50 ng / mL FGF, and about 25 ng / mL BMP4.
[0016] In some embodiments, the endothelial expansion medium comprises heparin and hydrocortisone. In some embodiments, the endothelial expansion medium comprises about 5-50 pg / mL heparin, and about 0.1-10 pg / mL hydrocortisone. In some embodiments, the endothelial expansion medium comprises about 12 pg / mL heparin, and about 1 pg / mL hydrocortisone.
[0017] In some embodiments, the endothelial expansion medium further comprises a ROCK inhibitor and / or a TGFP inhibitor. In some embodiments, the endothelial expansion medium further comprises about 5-20 pM ROCK inhibitor and / or about 5-20 pM TGFP inhibitor. In some embodiments, the endothelial expansion medium further comprises about 10 pM ROCK inhibitor and / or about 10 pM TGFP inhibitor. In some embodiments, the ROCK inhibitor is Y27632. In some embodiments, the TGFP inhibitor is SB431542.3MEI 52993232v.l127206-11520
[0018] In some embodiments, the endothelial expansion medium further comprises a ROCK inhibitor, a TGFp inhibitor, a Notch signaling inhibitor, and / or Forskolin. In some embodiments, the endothelial expansion medium further comprises about 5-20 pM ROCK inhibitor, about 5-20 M TGFp inhibitor, about 5-20 pM Notch signaling inhibitor, and / or about 5-20 pM Forskolin. In some embodiments, the Notch signaling inhibitor is DAPT. In some embodiments, the TGFp inhibitor is SB431542.
[0019] In some embodiments, the endothelial expansion medium further comprises a TGFp inhibitor, a Notch signaling inhibitor, and / or Forskolin. In some embodiments, the endothelial expansion medium further comprises about 5-20 pM TGFp inhibitor, about 5-20 pM Notch signaling inhibitor, and / or about 5-20 pM Forskolin. In some embodiments, the endothelial expansion medium further comprises about 5-20 pM Forskolin, about 5-20 pM DAPT, and / or about 5-20 pM SB431542. In some embodiments, the endothelial expansion medium further comprises about 5 pM Forskolin, about 5 pM DAPT, and / or about 5 pM SB431542.
[0020] In some embodiments, the endothelial expansion medium comprises heparin, hydrocortisone, a ROCK inhibitor and / or a TGFp inhibitor. In some embodiments, the endothelial expansion medium comprises about 5-50 pg / mL heparin, about 0.1-10 pg / mL hydrocortisone, about 5-20 pM ROCK inhibitor and / or about 5-20 pM TGFp inhibitor. In some embodiments, the endothelial expansion medium comprises about 12 pg / mL heparin, about 1 pg / mL hydrocortisone, about 10 pM ROCK inhibitor and / or about 10 pM TGFp inhibitor.
[0021] In some embodiments, the culturing in step (a) is performed for about 1 day.
[0022] In some embodiments, the culturing in step (a) is conducted under a normoxia condition of 5% CO2 and 20% O2.
[0023] In some embodiments, the culturing in step (b) is conducted under a hypoxia condition of 5% CO2 and 5% O2.
[0024] In some embodiments, the culturing in step (d) is conducted under a hypoxia condition of 5% CO2 and 5% O2.
[0025] In some embodiments, the culturing in step (d) is conducted under a normoxia condition of 5% CO2 and 20% O2.
[0026] In some embodiments, the pluripotent stem cells are cultured at a seeding density of about 2,500 to about 40,000 cells per cm2in step (a). In some embodiments, the pluripotent stem cells are cultured at a seeding density of about 5,000 to about 10,000 cells per cm2in step (a).4MEI 52993232v.l127206-11520
[0027] In some embodiments, the population of intermediate VPCs are replated at a seeding density of about 28,000 to about 172,000 cells per cm2in step (d).
[0028] In some embodiments, the method disclosed herein further comprises freezing the population of intermediate VPCs from step (c). In some embodiments, the population of intermediate VPCs are frozen for about 5 years or less. In some embodiments, the population of intermediate VPCs are frozen for about 1 years or less. In some embodiments, the population of intermediate VPCs are frozen for about 6 months or less. In some embodiments, the population of intermediate VPCs are frozen for about 1 month or less. In some embodiments, the population of intermediate VPCs are frozen at a temperature of about -70°C or less.
[0029] In some embodiments, the method disclosed herein further comprises thawing the population of intermediate VPCs prior to replating in step (d).
[0030] In some embodiments, the population of intermediate VPCs are replated in an endothelial expansion medium comprising heparin and hydrocortisone for 4 or more days.
[0031] In some embodiments, the population of intermediate VPCs are replated in an endothelial expansion medium comprising a ROCK inhibitor for about 2 or more days, and / or a TGFp inhibitor for about 4 or more days in step (d).
[0032] In some embodiments, the population of VPCs comprises about 30-80% CD31+CD144+ endothelial cells and about 20-70% CD140b+CD271+ MSC-like cells (e.g., as analyzed by flow cytometry).
[0033] In some embodiments, the endothelial cells are CD31+, CD144+ and CD271+. In some embodiments, the endothelial cells are about 70-100% CD146+ (e.g., as analyzed by flow cytometry). In some embodiments, the endothelial cells are about 60-90% CXCR4+ (e.g., as analyzed by flow cytometry).
[0034] In some embodiments, the population of VPCs has an about 20-60% decrease in the expression (e.g., as analyzed by flow cytometry) of one or more proteins selected from the group consisting of CD34 and CD43 as compared to the population of intermediate VPCs.
[0035] In some embodiments, the population of VPCs comprises about 40-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by single cell RNA-sequencing (scRNA-seq)).
[0036] In some embodiments, the population of VPCs comprises about 70-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq). In some embodiments, the population of VPCs comprises about5MEI 52993232v.l127206-1152075-85% CD31+CD144+ endothelial cells and about 15-25% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq). In some embodiments, the population of VPCs comprises about 80% CD31+CD144+ endothelial cells and about 20% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0037] In some embodiments, the endothelial cells are CD31+, CD144+ and CD271+.
[0038] In some embodiments, the endothelial cells are not CD31+, CD144- and RUNX1+.
[0039] In some embodiments, the population of VPCs comprises less than about 1% EPCAM+SOX17+ endoderm-like cells e.g., as analyzed by scRNA-seq).
[0040] In some embodiments, the population of VPCs does not comprise OCT4+NANOG+SOX2 undifferentiated pluripotent stem cells (e.g., as analyzed by scRNA-seq).
[0041] In some embodiments, the population of VPCs does not comprise OCT4+CDH2+ mesoderm cells (e.g., as analyzed by scRNA-seq).
[0042] In some embodiments, the endothelial population of VPCs has an about 80-130% increase in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CAV1, ANXA1, CD59, IGFBP3 and ANGPT2 as compared to the endothelial population of intermediate VPCs.
[0043] In some embodiments, the endothelial population of VPCs has an about 25-75% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of APOE, CD24 and DLK1 as compared to the endothelial population of intermediate VPCs.
[0044] In some embodiments, the endothelial population of VPCs has an about 20-50% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CD34, RUNX1, CD44 and SPN as compared to the endothelial population of intermediate VPCs.
[0045] In some embodiments, the endothelial population of VPCs has an about 40-90% increase in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CXCR4, EFNB2, and GJA4 as compared to the endothelial population of intermediate VPCs.
[0046] In some embodiments, the MSC-like population of VPCs has an about 30-60% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of ACTC1, BAMBI, HANDI, COL1A1, and COL1A2 as compared to the MSC-like population of intermediate VPCs.6MEI 52993232v.l127206-11520
[0047] In some embodiments, the population of VPCs secrets an increased level of one or more proteins selected from the group consisting of CCL2, FGF2, ANGPT1, AGNPT2, SDFla, HGF, Follistatin, EGF, and ANGPTL4 as compared to the population of intermediate VPCs (e.g., as analyzed by ELISA).
[0048] In some aspects, disclosed herein is a composition comprising a population of VPCs produced by the method disclosed herein.
[0049] In some aspects, disclosed herein is a composition comprising a population of VPCs produced by in vitro differentiation of pluripotent stem cells, wherein the population of VPCs comprises about 40-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0050] In some aspects, disclosed herein is a composition comprising a population of VPCs produced by in vitro differentiation of pluripotent stem cells, wherein the population of VPCs comprises about 70-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells e.g., as analyzed by scRNA-seq).
[0051] In some aspects, disclosed herein is a composition comprising a population of VPCs produced by in vitro differentiation of pluripotent stem cells, wherein the population of VPCs comprises about 75-85% CD31+CD144+ endothelial cells and about 15-25% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0052] In some aspects, disclosed herein is a composition comprising a population of VPCs produced by in vitro differentiation of pluripotent stem cells, wherein the population of VPCs comprises about 80% CD31+CD144+ endothelial cells and about 20% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0053] In some embodiments, the endothelial cells are CD31+, CD144+ and CD271+.
[0054] In some embodiments, the endothelial cells are not CD31+, CD 144- and RUNX1 +.
[0055] In some embodiments, the population of VPCs comprises less than about 1% EPCAM+SOX17+ endoderm-like cells (e.g., as analyzed by scRNA-seq).
[0056] In some embodiments, the population of VPCs does not comprise OCT4+NANOG+SOX2 undifferentiated pluripotent stem cells (e.g., as analyzed by scRNA-seq).
[0057] In some embodiments, the population of VPCs does not comprise OCT4+CDH2+ mesoderm cells (e.g., as analyzed by scRNA-seq).
[0058] In some embodiments, the endothelial population of VPCs has an about 80-130% increase in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected7MEI 52993232v.l127206-11520from the group consisting of CAV1, ANXA1, CD59, IGFBP3 and ANGPT2 as compared to the endothelial population of intermediate VPCs.
[0059] In some embodiments, the endothelial population of VPCs has an about 25-75% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of APOE, CD24 and DLK1 as compared to the endothelial population of intermediate VPCs.
[0060] In some embodiments, the endothelial population of VPCs has an about 20-50% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CD34, RUNX1, CD44 and SPN as compared to the endothelial population of intermediate VPCs.
[0061] In some embodiments, the endothelial population of VPCs has an about 40-90% increase in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CXCR4, EFNB2, and GJA4 as compared to the endothelial population of intermediate VPCs.
[0062] In some embodiments, the MSC-like population of VPCs has an about 30-60% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of ACTC1, BAMBI, HANDI, COL1A1, and COL1A2 as compared to the MSC-like population of intermediate VPCs.
[0063] In some embodiments, the population of VPCs secrets an increased level of one or more proteins selected from the group consisting of CCL2, FGF2, ANGPT1, AGNPT2, SDFla, HGF, Follistatin, EGF, and ANGPTE4 as compared to the population of intermediate VPCs (e.g., as analyzed by EEISA).
[0064] In some aspects, disclosed herein is a pharmaceutical composition comprising the population of VPCs of any preceding aspect and a pharmaceutically acceptable carrier.
[0065] In some embodiments, the pharmaceutically acceptable carrier is a cryopreservation media. In some embodiments, the pharmaceutically acceptable carrier is a cryopreservation media comprising about 5-10% DMSO.
[0066] In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel. In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from hyaluronic acid, chitosan, collagen, elastin, fibrin, fibrinogen, gelatin, alginate, cellulose, silk, fibrin, polyacrylic acid (PAA), polyethylene glycol (PEG), polylactic-co-glycolic acid, and / or Pluronic F-127. In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from8MEI 52993232v.l127206-11520homogenously deacetylated chitin (HDC). In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from crystalline cellulose / carmellose sodium (CMC-Na).
[0067] In some aspects, disclosed herein is a method of treating a vascular disease in a subject in need thereof, wherein the method comprises administering to the subject the composition of any preceding aspect, or the pharmaceutical composition of any preceding aspect, thereby treating the vascular disease in the subject.
[0068] In some embodiments, the administration of the composition or the pharmaceutical composition increases the blood flow, collateralization, arteriogenesis or capillary density in the subject.
[0069] In some embodiments, the administration of the composition or the pharmaceutical composition increases ankle-brachial index (ABI), increases tissue oxygenation, reduces ulcer / wound size, or promotes wound healing in the subject.
[0070] In some embodiments, the administration of the composition or the pharmaceutical composition promotes the angiogenesis and / or vasculogenesis in the subject.
[0071] In some embodiments, the administration of the composition or the pharmaceutical composition reduces the ischemic severity in the subject.
[0072] In some aspects, disclosed herein is a method of increasing blood flow in a subject suffering from, or suspected of suffering from, a vascular disease, wherein the method comprises administering to the subject the composition of any preceding aspect, or the pharmaceutical composition any preceding aspect, thereby increasing the blood flow in the subject.
[0073] In some aspects, disclosed herein is a method of increasing capillary density in a subject suffering from, or suspected of suffering from, a vascular disease, wherein the method comprises administering to the subject the composition of any preceding aspect, or the pharmaceutical composition of any preceding aspect, thereby increasing the capillary density in the subject.
[0074] In some aspects, disclosed herein is a method of reducing blood pressure in a subject suffering from, or suspected of suffering from, a vascular disease, wherein the method comprises administering to the subject the composition of any preceding aspect, or the pharmaceutical composition of any preceding aspect, thereby reducing the blood pressure in the subject.9MEI 52993232v.l127206-11520
[0075] In some aspects, disclosed herein is a method of promoting wound healing in a subject, wherein the wound comprises an impairment in the subject vasculature and wherein the method comprises administering to the subject the composition of any preceding aspect, or the pharmaceutical composition of any preceding aspect, thereby promoting wound healing in the subject.
[0076] In some embodiments, the vascular disease is selected from the group consisting of coronary artery diseases (e.g., arteriosclerosis, atherosclerosis, and other diseases or injuries of the arteries, arterioles and capillaries or related complaint), myocardial infarction (e.g., acute myocardial infarction), organizing myocardial infarct, ischemic heart disease, arrhythmia, left ventricular dilatation, emboli, heart failure, congestive heart failure, subendocardial fibrosis, left or right ventricular hypertrophy, myocarditis, chronic coronary ischemia, dilated cardiomyopathy, restenosis, arrhythmia, angina, hypertension (e.g., pulmonary hypertension, glomerular hypertension, portal hypertension), myocardial hypertrophy, peripheral arterial disease, intermittent claudication, critical limb ischemia, diabetic foot ulcer, cerebrovascular disease, renal artery stenosis, aortic aneurysm, pulmonary heart disease, cardiac dysrhythmias, inflammatory heart disease, congenital heart disease, rheumatic heart disease, diabetic vascular diseases, diabetic retinopathy, Buerger's disease, Reynaud's syndrome, acute limb ischemia, endothelial lung injury diseases (e.g., acute lung injury (ALI)), and acute respiratory distress syndrome (ARDS)).
[0077] In some embodiments, the vascular disease is critical limb ischemia.
[0078] In some embodiments, the vascular disease is diabetic vascular disease. In some embodiments, the vascular disease is diabetic retinopathy.
[0079] In some embodiments, the vascular disease is peripheral arterial disease (PAD).
[0080] In some embodiments, the vascular disease is intermittent claudication.
[0081] In some embodiments, the vascular disease is acute limb ischemia.
[0082] In some embodiments, the vascular disease is Buerger’s disease.
[0083] In some embodiments, the vascular disease is diabetic foot ulcer (DFU).
[0084] In some embodiments, the vascular disease is ARDS.
[0085] In some embodiments, the vascular disease is acute lung injury (ALI).
[0086] In some embodiments, the vascular disease is pulmonary arterial hypertension (PAH).
[0087] In some embodiments, the composition or the pharmaceutical composition is administered intramuscularly, intradermally, subcutaneously, or intraocularly. In some10MEI 52993232v.l127206-11520embodiments, the composition or the pharmaceutical composition is administered periarterially.
[0088] In some embodiments, the composition or the pharmaceutical composition is administered locally or systemically.
[0089] In some embodiments, the subject is a human subject.BRIEF DESCRIPTION OF THE DRAWINGS
[0090] FIG. 1 shows exemplary protocols for producing D6 intermediate vascular progenitor cells (VPCs) and D10 VPCs.
[0091] FIG. 2A shows UMAP (uniform manifold approximation and projection) dimensionality reduction and clustering of scRNA-seq data of D10 VPC, D6 VPC, human umbilical vein endothelial cells (HUVEC), and undifferentiated pluripotent stem cels (PSC).
[0092] FIG. 2B shows the UMAP clustering major cell populations present in the combined analysis of scRNA-seq data of D10 VPC, D6 VPC, HUVEC, and PSC, including MEST+ALCAM+ MSC-like cells, combined CD31+ cells, endoderm-like cells (EPCAM+ SOX17+), and early mesoderm cells (OCT4+CDH2+).
[0093] FIG. 2C shows UMAP clustering of scRNA-seq and reveals distinct subpopulations of D10 VPC (including MSC-like cells (MEST+ALCAM+) and endothelial cells CD31+CD144+)) and subpopulations of D6 VPC (including endoderm-like cells (EPCAM+SOX17+), early mesoderm cells (OCT4+CDH2+), MSC-like cells (MEST+AECAM+), myeloid / endothelial progenitor cells (C1)31+C1)144-RUNX1+). and endothelial cells (CD31+CD 144+)).
[0094] FIG. 3A shows a volcano plot depicting differentially expressed genes in D10 VPC endothelial cell clusters versus D6 VPC endothelial cell clusters. The average log2 Fold Change value is shown on the X-axis, and the absolute difference in percent of cell expressing is shown on the Y-axis. A positive log2FC value indicates that the genes are up-regulated in D10 VPC endothelial cell clusters as compared to D6 VPC endothelial cell clusters.
[0095] FIG. 3B displays plots showing expression levels of ANGPT2, CAV1, IGFBP3, ANXA1 and CD59 genes in different cell subpopulations from FIG. 2A (D10 VPC, D6 VPC, HUVEC and PSC).
[0096] FIG. 3C displays plots showing expression levels of APOE, CD24, and DLK1 genes in different cell subpopulations from FIG. 2 A (D10 VPC, D6 VPC, HUVEC and PSC).11MEI 52993232v.l127206-11520
[0097] FIG. 3D displays plots showing expression levels of PEC AMI, CD34, RUNX1, CDH5, CD44 and SPN genes in different cell subpopulations from FIG. 2 A (DIO VPC, D6 VPC, HUVEC and PSC).
[0098] FIG. 3E displays plots showing expression levels of EFNB2, CXCR4, GJA4, EPHB4, NR2F2, and NRP2 in different cell subpopulations from FIG. 2A (DIO VPC, D6 VPC, HUVEC and PSC).
[0099] FIG. 4A shows a volcano plot depicting differentially expressed genes in D10 MSC-like clusters versus D6 MSC-like clusters. The average log2 Fold Change value is shown on the X-axis, and the absolute difference in percent of cell expressing is shown on the Y-axis. A positive log2FC value indicates that the genes are up-regulated in D10 VPC MSC-like clusters as compared to D6 VPC MSC-like clusters.
[0100] FIG. 4B displays plots showing expression levels of ACTC1, AECAM, BAMBI, HAND1, COE1A1, and COE1A2 genes in different cell subpopulations from FIG. 2A (D10 VPC, D6 VPC, HUVEC and PSC).
[0101] FIG. 5A is a plot showing principal component analysis (PCA) of different cell surface markers as assessed by flow cytometry.
[0102] FIG. 5B displays graphs showing expression of PDPN and CD271 on D6 VPC and D10 VPC.
[0103] FIG. 5C displays graphs showing expression of CD31, CD34, CD 146, and CXCR4 on D6 VPC and D10 VPC.
[0104] FIG. 5D displays an exemplary flow plot showing expression of CD271 and CD31 on D10 VPC.
[0105] FIG. 6A displays bar graphs showing the levels of CCE2, FGF2, ANGPT1, ANGPT2, and SDFla secreted by D6 VPC, D10 VPC and bone marrow derived MSC (BM MSC) in cell culture media as analyzed by ELISA.
[0106] FIG. 6B displays bar graphs showing expression levels of HGF and follistatin secreted by D6 VPC, D10 VPC and BM MSC in cell culture media as analyzed by ELISA.
[0107] FIG. 6C displays bar graphs showing expression levels of Angiogenin, EGF, ANGPTL4, and MMP2 secreted by D6 VPC, D10 VPC and BM MSC in cell culture media as analyzed by ELISA.
[0108] FIG. 7A shows an overview of an exemplary method for testing the effects of VPC on regulating vascular tube formation.12MEI 52993232v.l127206-11520
[0109] FIG. 7B displays bar graphs showing results of in vitro function assessment on VPC, including percentages of HUVEC covered area, total tube length, total tube numbers, and total branch points.
[0110] FIG. 8A shows a graph of blood flow ratios (%) in db / db mice at various timepoints post ischemia-inducing surgery. Mice were injected with vehicle, D6 VPC (1 M dose), or D10 VPC (1 M dose) on Day 21 post surgery.
[0111] FIG. 8B displays bar graphs showing numbers of CD31+ vessels per imaging field of view (FOV) in mice receiving D6 VPC or D10 VPC, as assessed on Day 84 post ischemia-inducing surgery.
[0112] FIG. 8C shows a graph of blood flow ratios (%) in db / db mice at various timepoints post ischemia-inducing surgery. Mice were injected with vehicle, two lots of D10 VPC, at a total dose of IM, at either 2 injection sites, or 4 injections, on Day 21 post surgery.
[0113] FIG. 8D shows a graph of blood flow ratios (%) in db / db mice at various timepoints post ischemia-inducing surgery. Mice were injected with vehicle, two lots of D10 VPC, at a total dose of about 50 K, 100 K, 250 K, or IM, at 4 injections, on Day 21 post surgery.
[0114] FIG. 9 is a table showing fractions of D6 VPC, D10 VPC, and D14 VPC that are CD31+, CD144+, CD34+, CD43+, CD146+, CD140b+, CXCR4+, SSEA5+, CD271+, PDPN+, CD31+CD144+, CD34+CD144+, and CD43+CD144+.DETAILED DESCRIPTION OF THE INVENTION
[0115] The present disclosure provides a novel method for producing vascular progenitor cells (VPCs), which generates VPCs with unique phenotypes and improved efficacy in stabilizing tube formation of human endothelial cells in vitro and promoting angiogenesis and vasculogenesis in vivo.
[0116] In comparison with previous methods for VPC generation, the methods described herein utilize different medium and additives and include additional steps, such as, harvesting, freezing, thawing, and / or replating intermediate VPCs. The methods disclosed herein result in production of novel VPCs with two distinct subpopulations, endothelial cells and perivascular / mesenchymal stem cell (MSC)-like cells, while VPCs generated from previous methods have five to six subpopulations. Notably, said endothelial population of VPCs exhibit more matured phenotype. Advantageously, VPCs produced by the methods disclosed herein represent a more mature and enriched cell population that has a better safety13MEI 52993232v.l127206-11520profile, and shows improved efficacy in stabilizing tube formation of human endothelial cells in vitro and promoting angiogenesis in a diabetic mouse model.I. Definitions
[0117] In order that the present invention may be more readily understood, certain terms are first defined. It should also be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also part of this invention.
[0118] In the following description, for purposes of explanation, specific numbers, materials, and configurations are set forth in order to provide a thorough understanding of the invention. It will be apparent, however, to one having ordinary skill in the art that the invention may be practiced without these specific details. In some instances, well-known features may be omitted or simplified so as not to obscure the present invention.Furthermore, reference in the specification to phrases such as “one embodiment” or “an embodiment” mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. The appearances of phrases such as “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment.
[0119] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” refers to one element or more than one element.
[0120] The term “comprising” or “comprises” is used herein in reference to compositions, methods, and respective component(s) thereof, that are essential to the disclosure, yet open to the inclusion of unspecified elements, whether essential or not.
[0121] “Vascular progenitor cell” or “VPC” or “VPCs”, as used herein, refers to cells obtained by in vitro differentiation of pluripotent stem cells and that have the capacity to differentiate into endothelial, smooth muscle, pericytes, hematopoietic cell and mesenchymal cell lineages. VPCs may be useful for treating a vascular disease as defined herein. In another embodiment, the VPCs may be generated in vitro from pluripotent stem cells according to the methods described in Example 1 below and shown in FIG. 1.
[0122] “Pluripotent stem cell,” as used herein, refers broadly to a cell capable of prolonged or virtually indefinite proliferation in vitro while retaining their undifferentiated state, and having the capacity to differentiate into all three germ layers (i.e., ectoderm, mesoderm and endoderm) under the appropriate conditions. Pluripotent stem cells are14MEI 52993232v.l127206-11520typically defined functionally as stem cells that are: (a) capable of inducing teratomas when transplanted in immunodeficient (SCID) mice; (b) capable of differentiating to cell types of all three germ layers (e.g., can differentiate to ectodermal, mesodermal, and endodermal cell types); and (c) express one or more markers of embryonic stem cells (e.g., Oct 4, alkaline phosphatase. SSEA-3 surface antigen, SSEA-4 surface antigen, nanog, TRA-1-60, TRA-1-81, SOX2, REXI, etc.). In certain embodiments, pluripotent stem cells express one or more markers selected from the group consisting of: OCT-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. Exemplary pluripotent stem cells can be generated using, for example, methods known in the art.
[0123] Pluripotent stem cells include, but are not limited to, embryonic stem cells, induced pluripotent stem (iPS) cells, embryo-derived cells (EDCs), adult stem cells, hematopoietic cells, fetal stem cells, mesenchymal stem cells, postpartum stem cells, or embryonic germ cells. In an embodiment, the pluripotent stem cells are mammalian pluripotent stem cells. In another embodiment, the pluripotent stem cells are human pluripotent stem cells including, but not limited to, human embryonic stem (hES) cells, human induced pluripotent stem (iPS) cells, human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. In one embodiment, the pluripotent stem cell is human embryonic stem cell. In another embodiment, the pluripotent stem cell is human induced pluripotent stem cell. In another embodiment, the pluripotent stem cells may be a pluripotent stem cell listed in the Human Pluripotent Stem Cell Registry, hPSCreg. Pluripotent stem cells may be genetically modified or otherwise modified to increase longevity, potency, homing, to prevent or reduce alloimmune responses or to deliver a desired factor in cells that are differentiated from such pluripotent cells.
[0124] The pluripotent stem cells may be from any species. Embryonic stem cells have been successfully derived from, for example, mice, multiple species of non-human primates, and humans, and embryonic stem-like cells have been generated from numerous additional species. Thus, one of skill in the art can generate embryonic stem cells and embryo-derived stem cells from any species, including but not limited to, human, non-human primates, rodents (mice, rats), ungulates (cows, sheep, etc.), dogs (domestic and wild dogs), cats (domestic and wild cats such as lions, tigers, cheetahs), rabbits, hamsters, gerbils, squirrel, guinea pig, goats, elephants, panda (including giant panda), pigs, raccoon, horse, zebra, marine mammals (dolphin, whales, etc.) and the like.15MEI 52993232v.l127206-11520
[0125] “Embryonic stem cells” (ES cells), as used herein, refers broadly to cells derived from the inner cell mass of blastocysts or morulae that have been serially passaged as cell lines. The ES cells may be derived from fertilization of an egg cell with sperm or DNA, nuclear transfer, parthenogenesis, or by means to generate ES cells with homozygosity in the HLA region. ES cells may also refer to cells derived from a zygote, blastomeres, or blastocyst-staged mammalian embryo produced by the fusion of a sperm and egg cell, nuclear transfer, parthenogenesis, or the reprogramming of chromatin and subsequent incorporation of the reprogrammed chromatin into a plasma membrane to produce a cell, optionally without destroying the remainder of the embryo. Embryonic stem cells, regardless of their source or the particular method used to produce them, may be identified based on one or more of the following features: (i) ability to differentiate into cells of all three germ layers, (ii) expression of at least Oct-4 and alkaline phosphatase, and (iii) ability to produce teratomas when transplanted into immunocompromised animals.
[0126] “Induced pluripotent stem cells” or “iPS cells,” as used herein, generally refer to pluripotent stem cells obtained by reprogramming a somatic cell. An iPS cell may be generated by expressing or inducing expression of a combination of factors ("reprogramming factors"), for example, Oct 4 (sometimes referred to as Oct 3 / 4), Sox2, Myc (eg. c-Myc or any Myc variant), Nanog, Lin28, and Klf4, in a somatic cell. In an embodiment, the reprogramming factors comprise Oct 4, Sox2, c-Myc, and Klf4. In another embodiment, reprogramming factors comprise Oct 4, Sox2, Nanog, and Lin28. In certain embodiments, at least two reprogramming factors are expressed in a somatic cell to successfully reprogram the somatic cell. In other embodiments, at least three reprogramming factors are expressed in a somatic cell to successfully reprogram the somatic cell. In other embodiments, at least four reprogramming factors are expressed in a somatic cell to successfully reprogram the somatic cell. In another embodiment, at least five reprogramming factors are expressed in a somatic cell to successfully reprogram the somatic cell. In yet another embodiment, at least six reprogramming factors are expressed in the somatic cell, for example, Oct 4, Sox2, c-Myc, Nanog, Lin28, and Klf4. In other embodiments, additional reprogramming factors are identified and used alone or in combination with one or more known reprogramming factors to reprogram a somatic cell to a pluripotent stem cell.
[0127] iPS cells may be generated using fetal, postnatal, newborn, juvenile, or adult somatic cells. Somatic cells may include, but are not limited to, fibroblasts, keratinocytes, adipocytes, muscle cells, organ and tissue cells, and various blood cells including, but not16MEI 52993232v.l127206-11520limited to, hematopoietic cells (eg. hematopoietic stem cells). In an embodiment, the somatic cells are fibroblast cells, such as a dermal fibroblast, synovial fibroblast, or lung fibroblast, or a non-fibroblastic somatic cell.
[0128] iPS cells may be obtained from a cell bank. Alternatively, IPS cells may be newly generated by methods known in the art. iPS cells may be specifically generated using material, from a particular patient or matched donor with the goal of generating tissue-matched cells. In an embodiment, iPS cells may be universal donor cells that are not substantially immunogenic.
[0129] The induced pluripotent stem cell may be produced by expressing or inducing the expression of one or more reprogramming factors in a somatic cell. Reprogramming factors may be expressed in the somatic cell by infection using a viral vector, such as a retroviral vector or a lentiviral vector. CRISPR / Talen / zinc-finger neucleases (XFNs) may also be used. Also, reprogramming factors may be expressed in the somatic cell using a non-integrative vector, such as an episomal plasmid, or RNA. When reprogramming factors are expressed using non-integrative vectors, the factors may be expressed in the cells using electroporation, transfection, or transformation of the somatic cells with the vectors. For example, in mouse cells, expression of four factors (Oct3 / 4, Sox2, c-myc, and Klf4) using integrative viral vectors is sufficient to reprogram a somatic cell. In human cells, expression of four factors (Oct3 / 4, Sox2, NANOG, and Lin28) using integrative viral vectors is sufficient to reprogram a somatic cell.
[0130] Expression of the reprogramming factors may be induced by contacting the somatic cells with at least one agent, such as a small organic molecule agents, that induce expression of reprogramming factors.
[0131] The somatic cell may also be reprogrammed using a combinatorial approach wherein the reprogramming factor is expressed (e.g., using a viral vector, plasmid, and the like) and the expression of the reprogramming factor is induced (e.g. using a small organic molecule.)
[0132] Once the reprogramming factors are expressed or induced in the cells, the cells may be cultured. Over time, cells with ES characteristics appear in the culture dish. The cells may be chosen and subcultured based on, for example, ES cell morphology, or based on expression of a selectable or detectable marker. The cells may be cultured to produce a culture of cells that resemble ES cells.17MEI 52993232v.l127206-11520
[0133] To confirm the pluripotency of the iPS cells, the cells may be tested in one or more assays of pluripotency. For examples, the cells may be tested for expression of ES cell markers; the cells may be evaluated for ability to produce teratomas when transplanted into SCID mice; the cells may be evaluated for ability to differentiate to produce cell types of all three germ layers.
[0134] iPS cells may be from any species. These iPS cells have been successfully generated using mouse and human cells. Furthermore, iPS cells have been successfully generated using embryonic, fetal, newborn, and adult tissue. Accordingly, one may readily generate iPS cells using a donor cell from any species. Thus, one may generate iPS cells from any species, including but not limited to, human, non-human primates, rodents (mice, rats), ungulates (cows, sheep, etc.), dogs (domestic and wild dogs), cats (domestic and wild cats such as lions, tigers, cheetahs), rabbits, hamsters, goats, elephants, panda (including giant panda), pigs, raccoon, horse, zebra, marine mammals (dolphin, whales, etc.) and the like.
[0135] When a cell is characterized as being “positive” or “+” for a given marker, it may be a low (lo), intermediate (int), and / or high (hi) expresser of that marker depending on the degree to which the marker is present on a cell surface of a cell or within a population of cells, where the terms relate to intensity of fluorescence or other color used in the color sorting process of the cells. The distinction of lo, int, and hi will be understood in the context of the marker used on a particular cell population being sorted. When a cell is characterized as being “negative” or for a given marker, it means that a cell or a population of cells may not express that marker or that the marker may be expressed at a relatively very low level by that cell or a population of cells, and that it generates a very low signal when detectably labeled.
[0136] In an embodiment of the invention, if the level of expression of a marker is greater than 60%, 70%, 80%, or 90% relative to a control, the cell or population of cells is characterized as expressing high (hi) levels of the marker. In another embodiment, if the level of expression of a marker is between about 20%, 30%, 40%, 50% to about 60% relative to a control, the cell or a population of cells is characterized as expression intermediate (int) levels of the marker. In yet another embodiment, if the level of expression of a marker is between about 2%, 5%, 10%, or 15% to about 20% relative to a control, the cell or a population of cells is characterized as expression low (lo) levels of the marker. In a further embodiment, if the level of expression of a marker is less than about 2%, 1.5%, 1%, or 0.5% relative to a control, the cell or population of cells is characterized as being negative for the18MEI 52993232v.l127206-11520marker. A “control” may be any control or standard familiar to one of ordinary skill in the art useful for comparison purposes and may include a negative control or a positive control.
[0137] “Treatment” or “treating” as used herein, refers to curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, affecting, preventing, or delaying the onset of a disease or disorder, or symptoms of the disease or disorder. In the context of vascular repair, the term “treatment” or “treating” includes repairing, replacing, augmenting, improving, rescuing, repopulating, or regenerating vascular tissue.II. Method of Producing VPCs
[0138] The present invention provides methods of producing a population of novel vascular progenitor cells (VPCs) by in vitro differentiation of pluripotent stem cells. The methods comprise (a) culturing the pluripotent stem cells on an extracellular matrix surface in a pluripotent stem cell expansion medium, (b) culturing the pluripotent stem cells from step (a) on an extracellular matrix surface in a VPC differentiation medium comprising vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and bone morphogenetic protein 4 (BMP4) for about 6 days to produce a population of intermediate VPCs, (c) harvesting the population of intermediate VPCs from step (b); and (d) replating the population of intermediate VPCs from step (c) on an extracellular matrix surface in an endothelial expansion medium for about 4 or more days, thereby producing the population of VPCs.
[0139] Pluripotent stems cells for use in the methods of the present invention can be obtained and cultured by any of the methods known in the art. In one embodiment, pluripotent stem cells, e.g., human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs), are cultured in feeder-free (FF) conditions and plated on an extracellular matrix. In one embodiment, the pluripotent stem cells are cultured on a feeder cell layer and plated on an extracellular matrix.
[0140] In some embodiments, the extracellular matrix is selected from the group consisting of collagen, collagen I, collagen IV, laminin, fibronectin, vitronectin, proteoglycan, entactin, heparan sulfate, a soluble preparation from Engelbreth-Holm- Swarm (EHS) mouse sarcoma cells, Matrigel® (Coming), gelatin, and a human basement membrane extract. In one embodiment, the extracellular matrix may be derived from any mammalian, including human, origin. In one embodiment, the extracellular matrix surface for culturing19MEI 52993232v.l127206-11520the pluripotent stem cells is a collagen-IV-coated surface, e.g., a human collagen-IV-coated surface.
[0141] In some embodiments, the pluripotent stem cells are cultured in a medium suitable for supporting pluripotency, e.g., a pluripotent stem cell expansion medium, and any such medium are known in the art. In some embodiments, the pluripotent stem cell expansion medium is StemFit™. In some embodiments, the pluripotent stem cell expansion medium is Nutristem™. In some embodiments, the pluripotent stem cell expansion medium is TeSR™.
[0142] In some embodiments, the pluripotent stem cell expansion medium comprises a Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor.
[0143] In some embodiments, the pluripotent stem cell expansion medium comprises about 5-20 pM ROCK inhibitor (for example, about 5-18 pM, 5-16 pM, 5-14 pM, 5-12 pM, 7-15 pM, 7-14 pM, 7-13 pM, 7-12 pM, 8-15 pM, 8-14 pM, 8-13 pM, or 8-12 pM ROCK inhibitor). In some embodiments, the pluripotent stem cell expansion medium comprises about 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 11 pM, 12 pM, 13 pM, 14 pM, 15 pM, 16 pM, 17 pM, 18 pM, 19 pM, or 20 pM ROCK inhibitor. In some embodiments, the pluripotent stem cell expansion medium comprises about 10 pM ROCK inhibitor. In some embodiments, the ROCK inhibitor is Y27632. The chemical structure of Y27632 is as shown below:
[0144] In some embodiments, the pluripotent stem cells may be cultured under a normoxia condition of about 5% CO2 and about 20% O2, or other known conditions suitable for the growth of pluripotent stem cells.
[0145] In some embodiments, the pluripotent stem cells are plated and cultured for about 1 hour to about 24 hours in the culture media to let the cells settle before inducing differentiation. In some embodiments, the pluripotent stem cells are cultured for about 1 day before inducing differentiation.
[0146] To induce the differentiation of pluripotent stem cells into VPCs, the pluripotent stem cells may be cultured in a VPC differentiation medium under hypoxic conditions (e.g., 5% CO2 and 5% O2). In some embodiments, the pluripotent stem cells may be cultured in a VPC differentiation medium under adherent conditions. Adherent conditions may include 20MEI 52993232v.l127206-11520culturing the cells on an extracellular matrix, such as collagen IV, Matrigel®, fibronectin, or gelatin. In one embodiment, the extracellular matrix surface for differentiating the pluripotent stem cells is a collagen-IV-coated surface, e.g., a human collagen-IV-coated surface.
[0147] The VPC differentiation medium may comprise a basal medium, such as StemSpan Medium, Stemline® II Hematopoietic Stem Cell Expansion Medium (Sigma), Iscove’s Modified Dulbecco’s Medium (IMDM), Dulbecco’s Modified Eagle’s Medium (DMEM), or any other known basal medium. In some embodiments, the differentiation medium is StemSpan medium.
[0148] The VPC differentiation medium may further comprise factors for inducing the differentiation of the pluripotent stem cells into VPCs, such as bone morphogenic protein 4 (BMP4), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF).
[0149] In some embodiments, the VPC differentiation medium comprises about 5-100 ng / mE VEGF (e.g., about 5-90 ng / mL, 10-90 ng / mL, 20-90 ng / mL, 30-90 ng / mL, 40-90 ng / mL, 10-80 ng / mL, 20-80 ng / mL, 30-80 ng / mL, 40-80 ng / mL, 20-70 ng / mL, 30-70 ng / mL, 40-70 ng / mL, 20-60 ng / mL, 30-60 ng / mL, 40-60 ng / mL, or 45-55 ng / mL VEGF). In some embodiments, the VPC differentiation medium comprises about 5 ng / mL, 10 ng / mL, 15 ng / mL, 20 ng / mL, 25 ng / mL, 30 ng / mL, 35 ng / mL, 40 ng / mL, 45 ng / mL, 50 ng / mL, 55 ng / mL, 60 ng / mL, 65 ng / mL, 70 ng / mL, 75 ng / mL, 80 ng / mL, 85 ng / mL, 90 ng / mL, 95 ng / mL, or 100 ng / mL VEGF.
[0150] In some embodiments, the VPC differentiation medium comprises about 5-100 ng / mL FGF (e.g., about 5-90 ng / mL, 10-90 ng / mL, 20-90 ng / mL, 30-90 ng / mL, 40-90 ng / mL, 10-80 ng / mL, 20-80 ng / mL, 30-80 ng / mL, 40-80 ng / mL, 20-70 ng / mL, 30-70 ng / mL, 40-70 ng / mL, 20-60 ng / mL, 30-60 ng / mL, 40-60 ng / mL, or 45-55 ng / mL FGF). In some embodiments, the VPC differentiation medium comprises about 5 ng / mL, 10 ng / mL, 15 ng / mL, 20 ng / mL, 25 ng / mL, 30 ng / mL, 35 ng / mL, 40 ng / mL, 45 ng / mL, 50 ng / mL, 55 ng / mL, 60 ng / mL, 65 ng / mL, 70 ng / mL, 75 ng / mL, 80 ng / mL, 85 ng / mL, 90 ng / mL, 95 ng / mL, or 100 ng / mL FGF. In some embodiments, the FGF is FGF2.
[0151] In some embodiments, the VPC differentiation medium comprises about 5-100 ng / mL BMP4 (e.g., about 5-90 ng / mL, 10-90 ng / mL, 20-90 ng / mL, 30-90 ng / mL, 40-90 ng / mL, 10-80 ng / mL, 20-80 ng / mL, 30-80 ng / mL, 40-80 ng / mL, 20-70 ng / mL, 30-70 ng / mL, 40-70 ng / mL, 20-60 ng / mL, 30-60 ng / mL, 40-60 ng / mL, 45-55 ng / mL, 10-40 ng / mL, 15-35 ng / mL, or 20-30 ng / mL BMP4). In some embodiments, the VPC differentiation medium comprises about 5 ng / mL, 10 ng / mL, 15 ng / mL, 20 ng / mL, 25 ng / mL, 30 ng / mL, 35 ng / mL,21MEI 52993232v.l127206-1152040 ng / mL, 45 ng / mL, 50 ng / mL, 55 ng / mL, 60 ng / mL, 65 ng / mL, 70 ng / mL, 75 ng / mL, 80 ng / mL, 85 ng / mL, 90 ng / mL, 95 ng / mL, or 100 ng / mL BMP4.
[0152] In some embodiments, the VPC differentiation medium comprises about 5-50 ng / mL VEGF, about 5-50 ng / mL FGF (e.g., FGF2), and about 5-25 ng / mL BMP4.
[0153] In some embodiments, the VPC differentiation medium comprises about 50 ng / mL VEGF, about 50 ng / mL FGF (e.g., FGF2), and about 25 ng / mL BMP4.
[0154] The pluripotent stem cells may be cultured in the differentiation medium for about 1-14 days, or about 2-10 days, or about 3-8 days, or about 4, 5, 6, 7, 8, 9 or 10 days, or until the pluripotent stem cells differentiate into VPCs.
[0155] In one embodiment, the pluripotent stem cells are cultured in the VPC differentiation medium for about 6 days or longer. In some embodiments, the pluripotent stem cells are cultured in the VPC differentiation medium for about 6 days to produce a population of intermediate VPCs. The intermediate VPCs are subsequently harvested and replated in an endothelial expansion medium for about 4 or more days (e.g., about 4, 5, 6, 7 or 8 days), thereby producing VPCs.
[0156] In some embodiments, the pluripotent stem cells are cultured in a VPC differentiation medium for about 6 days to produce a population of intermediate VPCs. The intermediate VPCs are subsequently harvested, frozen, thawed, and then replated in an endothelial expansion medium for about 4 or more days (e.g., about 4, 5, 6, 7 or 8 days), thereby producing VPCs.
[0157] In some embodiments, the intermediate VPCs may be cultured in an endothelial expansion medium under a hypoxic condition (e.g., 5% CO2 and 5% O2). In some embodiments, the intermediate VPCs may be cultured in an endothelial expansion medium under a normoxia condition (e.g., 5% CO2 and 20% O2)
[0158] The endothelial expansion medium may comprise a basal medium, such as StemDiff endothelial expansion medium, Stem MACS medium, StemLine II medium, StemSpan medium, or any other known basal medium. In some embodiments, the endothelial expansion medium is StemDiff endothelial expansion medium.
[0159] In some embodiments, the endothelial expansion medium comprises heparin and / or hydrocortisone. In some embodiments, the endothelial expansion medium comprises about 5-100 pg / mL heparin (e.g., about 5-90 pg / mL, 5-50 pg / mL, 10-90 pg / mL, 20-90 pg / mL, 30-90 pg / mL, 40-90 pg / mL, 10-80 pg / mL, 20-80 pg / mL, 30-80 pg / mL, 40-80 pg / mL, 20-70 pg / mL, 30-70 pg / mL, 40-70 pg / mL, 20-60 pg / mL, 30-60 pg / mL, 40-6022MEI 52993232v.l127206-11520pg / mL, 45-55 pg / mL, 5-30 pg / mL, 10-25 pg / mL, or about 10-15 pg / mL heparin). In some embodiments, the endothelial expansion medium comprises about 5 pg / mL, 8 g / mL, 10 pg / mL, 11 pg / mL, 12 pg / mL, 13 pg / mL, 14 pg / mL, 15 pg / mL, 16 pg / mL, 17 pg / mL, 18 pg / mL, 20 pg / mL, 25 pg / mL, 30 pg / mL, 35 pg / mL, 40 pg / mL, 45 pg / mL, 50 pg / mL, 55 pg / mL, 60 pg / mL, 65 pg / mL, 70 pg / mL, 75 pg / mL, 80 pg / mL, 85 pg / mL, 90 pg / mL, 95 pg / mL, or 100 pg / mL heparin.
[0160] In some embodiments, the endothelial expansion medium comprises about 0.1-10 pg / mL hydrocortisone (e.g., about 0.1-10 pg / mL, 0.1-8 pg / mL, 0.1-9 pg / mL, 0.1-8 pg / mL, 0.1-7 pg / mL, 0.1-6 pg / mL, 0.1-5 pg / mL, 0.1-4 pg / mL, 0.1-3 pg / mL, 0.1-2 pg / mL, 0.1-1 pg / mL, 0.5-10 pg / mL, 0.5-8 pg / mL, 0.5-9 pg / mL, 0.5-8 pg / mL, 0.5-7 pg / mL, 0.5-6 pg / mL, 0.5-5 pg / mL, 0.5-4 pg / mL, 0.5-3 pg / mL, 0.5-2 pg / mL, or 0.5-1 pg / mL hydrocortisone). In some embodiments, the endothelial expansion medium comprises about 0.1 pg / mL, 0.2 pg / mL, 0.3 pg / mL, 0.4 pg / mL, 0.5 pg / mL, 0.6 pg / mL, 0.7 pg / mL, 0.8 pg / mL, 0.9 pg / mL, 1 pg / mL, 1.1 pg / mL, 1.2 pg / mL, 1.3 pg / mL, 1.4 pg / mL, 1.5 pg / mL, 1.6 pg / mL, 1.7 pg / mL, 1.8 pg / mL, 1.9 pg / mL, 2 pg / mL, 2.5 pg / mL, 3 pg / mL, 3.5 pg / mL, 4 pg / mL, 4.5 pg / mL, 5 pg / mL, 6 pg / mL, 7 pg / mL, 8 pg / mL, 9 pg / mL or 10 pg / mL hydrocortisone.
[0161] In some embodiments, the endothelial expansion medium comprises about 5-50 pg / mL heparin, and about 0.1-10 pg / mL hydrocortisone. In some embodiments, the endothelial expansion medium comprises about 12 pg / mL heparin, and about 1 pg / mL hydrocortisone.
[0162] In some embodiments, the endothelial expansion medium further comprises a ROCK inhibitor and / or a TGFp inhibitor.
[0163] In some embodiments, the endothelial expansion medium further comprises about 5-20 pM ROCK inhibitor (e.g., about 5-18 pM, 5-16 pM, 5-14 pM, 5-12 pM, 7-15 pM, 7-14 pM, 7-13 pM, 7-12 pM, 8-15 pM, 8-14 pM, 8-13 pM, or 8-12 pM ROCK inhibitor). In some embodiments, the endothelial expansion medium further comprises about 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 11 pM, 12 pM, 13 pM, 14 pM, 15 pM, 16 pM, 17 pM, 18 pM, 19 pM, or 20 pM ROCK inhibitor.
[0164] In some embodiments, the endothelial expansion medium further comprises about 5-20 pM TGFp inhibitor (e.g., about 5-18 pM, 5-16 pM, 5-14 pM, 5-12 pM, 7-15 pM, 7-14 pM, 7-13 pM, 7-12 pM, 8-15 pM, 8-14 pM, 8-13 pM, or 8-12 pM ROCK inhibitor). In some embodiments, the endothelial expansion medium further comprises about 5 pM, 6 pM, 7 pM,23MEI 52993232v.l127206-115208 pM, 9 pM, 10 pM, 11 pM, 12 pM, 13 pM, 14 pM, 15 pM, 16 pM, 17 pM, 18 pM, 19 pM, or 20 p M TGFp inhibitor.
[0165] In some embodiments, the endothelial expansion medium further comprises about 5-20 pM ROCK inhibitor and about 5-20 p M TGFp inhibitor. In some embodiments, the endothelial expansion medium further comprises about 10 pM ROCK inhibitor and / or about 10 pM TGFP inhibitor.
[0166] In some embodiments, the endothelial expansion medium comprises heparin, hydrocortisone, a ROCK inhibitor and / or a TGFp inhibitor. In some embodiments, the endothelial expansion medium comprises about 5-50 pg / mL heparin, about 0.1-10 pg / mL hydrocortisone, about 5-20 pM ROCK inhibitor and / or about 5-20 pM TGFp inhibitor. In some embodiments, the endothelial expansion medium comprises about 12 pg / mL heparin, about 1 pg / mL hydrocortisone, about 10 pM ROCK inhibitor and / or about 10 pM TGFp inhibitor.
[0167] In some embodiments, the endothelial expansion medium comprises heparin, hydrocortisone, and / or a ROCK inhibitor. In some embodiments, the endothelial expansion medium comprises about 5-50 pg / mL heparin, about 0.1-10 pg / mL hydrocortisone, and / or about 5-20 pM ROCK inhibitor. In some embodiments, the endothelial expansion medium comprises about 12 pg / mL heparin, about 1 pg / mL hydrocortisone, and / or about 10 pM ROCK inhibitor.
[0168] In some embodiments, the endothelial expansion medium comprises heparin, hydrocortisone, and / or a TGFp inhibitor. In some embodiments, the endothelial expansion medium comprises about 5-50 pg / mL heparin, about 0.1-10 pg / mL hydrocortisone, and / or about 5-20 pM TGFp inhibitor. In some embodiments, the endothelial expansion medium comprises about 12 pg / mL heparin, about 1 pg / mL hydrocortisone, and / or about 10 pM TGFP inhibitor.
[0169] In some embodiments, the ROCK inhibitor is Y27632. In some embodiments, the TGFp inhibitor is SB431542. The chemical structure of SB431542 is as shown below:24MEI 52993232v.l127206-11520
[0170] In some embodiments, the endothelial expansion medium further comprises a Notch signaling inhibitor, e.g., DAPT. In some embodiments, the endothelial expansion medium further comprises about 5-20 pM (e.g., about 5-18 pM, 5-16 pM, 5-14 pM, 5-12 pM, 7-15 pM, 7-14 pM, 7-13 pM, 7-12 pM, 8-15 pM, 8-14 pM, 8-13 pM, or 8-12 pM) Notch signaling inhibitor, e.g., DAPT. In some embodiments, the endothelial expansion medium further comprises about 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 11 pM, 12 pM, 13 pM, 14 pM, 15 pM, 16 pM, 17 pM, 18 pM, 19 pM, or 20 pM Notch signaling inhibitor, e.g., DAPT.
[0171] In some embodiments, the endothelial expansion medium further comprises a small molecule that increases the level of cyclic AMP, e.g., Forskolin. In some embodiments, the endothelial expansion medium further comprises about 5-20 pM e.g., about 5-18 pM, 5-16 pM, 5-14 pM, 5-12 pM, 7-15 pM, 7-14 pM, 7-13 pM, 7-12 pM, 8-15 pM, 8-14 pM, 8-13 pM, or 8-12 pM) Forskolin. In some embodiments, the endothelial expansion medium further comprises about 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 11 pM, 12 pM, 13 pM, 14 pM, 15 pM, 16 pM, 17 pM, 18 pM, 19 pM, or 20 pM Forskolin.
[0172] In some embodiments, the endothelial expansion medium further comprises about 5-20 pM Forskolin, about 5-20 pM DAPT, and about 5-20 pM SB431542.
[0173] In some embodiments, the pluripotent stem cells are cultured at a seeding density of about 1,000 to about 50,000 cells per cm2(e.g., about 1,000 to about 50,000 cells per cm2, about 1,000 to about 30,000 cells per cm2, about 1,000 to about 20,000 cells per cm2, about 1,000 to about 10,000 cells per cm2, about 2,500 to about 40,000 cells per cm2, about 3,000 to about 30,000 cells per cm2, or about 5,000 to about 30,000 cells per cm2) in step (a). In some embodiments, the pluripotent stem cells are cultured at a seeding density of about 1,000 cells per cm2, about 2,500 cells per cm2, about 3,000 cells per cm2, about 4,000 cells per cm2, about 5,000 cells per cm2, about 8,000 cells per cm2, about 10,000 cells per cm2, about 15,000 cells per cm2, or about 20,000 cells per cm2in step (a).
[0174] In some embodiments, the pluripotent stem cells are cultured at a seeding density of about 2,500 to about 40,000 cells per cm2in step (a). In some embodiments, the pluripotent stem cells are cultured at a seeding density of about 5,000 to about 10,000 cells per cm2in step (a).
[0175] In some embodiments, the population of intermediate VPCs are replated at a seeding density of about 10,000 to about 500,000 cells per cm2(e.g., about 10,000 to about 400,000 cells per cm2, about 15,000 to about 300,000 cells per cm2, about 20,000 to about25MEI 52993232v.l127206-11520250,000 cells per cm2, about 20,000 to about 200,000 cells per cm2, about 25,000 to about 200,000 cells per cm2, about 20,000 to about 100,000 cells per cm2, about 26,000 to about 180,000 cells per cm2, or about 28,000 to about 172,000 cells per cm2) in step (d).
[0176] In some embodiments, the population of intermediate VPCs are replated at a seeding density of about 10,000 to about 400,000 cells per cm2in step (d). In some embodiments, the population of intermediate VPCs are replated at a seeding density of about 28,000 to about 172,000 cells per cm2in step (d).
[0177] In some embodiments, the method of any preceding aspect further comprises freezing the population of intermediate VPCs from step (c).
[0178] In some embodiments, the population of intermediate VPCs are frozen for about 5 years or less. In some embodiments, the population of intermediate VPCs are frozen for about 1 years or less. In some embodiments, the population of intermediate VPCs are frozen for about 6 months or less. In some embodiments, the population of intermediate VPCs are frozen for about 1 month or less.
[0179] In some embodiments, the population of intermediate VPCs are frozen at a temperature of about -70°C or less.
[0180] In some examples, the method disclosed herein further comprises thawing the population of intermediate VPCs prior to replating in step (d).
[0181] In some embodiments, the population of intermediate VPCs are replated in an endothelial expansion medium comprising a ROCK inhibitor for about 2 or more days, and / or a TGFp inhibitor for about 4 or more days in step (d).
[0182] In another aspect, provided herein is a method for producing a population of vascular progenitor cells (VPCs) by in vitro differentiation of pluripotent stem cells, wherein the method comprises (a) culturing the pluripotent stem cells on an extracellular matrix surface in a pluripotent stem cell expansion medium, (b) culturing the pluripotent stem cells from step (a) on an extracellular matrix surface in a VPC differentiation medium comprising vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and bone morphogenetic protein 4 (BMP4) for about 6 days to produce a population of intermediate VPCs, (c) harvesting and freezing the population of intermediate VPCs from step (b); (d) thawing the population of intermediate VPCs from step (c); and (e) replating the population of intermediate VPCs from step (d) on an extracellular matrix surface in an endothelial expansion medium for about 4 or more days, thereby producing the population of VPCs.26MEI 52993232v.l127206-11520III. Compositions of VPCs
[0183] The present invention provides novel VPCs obtained by in vitro differentiation of pluripotent stem cells using the methods disclosed herein. The VPCs of the present invention exhibit a more mature phenotype, with improved safety profile and efficacy both in vitro and in vivo.
[0184] The VPCs produced by the methods disclosed herein may be characterized based on certain structural and functional properties including, but not limited to, the expression of or lack of expression of certain DNA, RNA, microRNA, or protein.
[0185] In some embodiments, the population of VPCs comprises about 30-80% CD31+CD144+ endothelial cells (e.g., about 30-75%, about 30-70%, about 30-60%, about 30-50%, about 40-80%, or about 50-80% CD31+CD144+ endothelial cells, e.g., as analyzed by flow cytometry). In some embodiments, the population of VPCs comprises about 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, or 80% CD31+CD144+ endothelial cells (e.g., as analyzed by flow cytometry).
[0186] In some embodiments, the population of VPCs comprises about 20-70% CD140b+CD271+ MSC-like cells (e.g., about 20-65%, about 20-60%, about 20-50%, about 20-40%, about 30-70%, about 30-60%, or about 40-60% CD140b+CD271+ MSC-like cells, e.g., as analyzed by flow cytometry). In some embodiments, the population of VPCs comprises about 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, or 70% CD140b+CD271+ MSC-like cells (e.g., as analyzed by flow cytometry).
[0187] In some embodiments, the population of VPCs comprises about 30-80% CD31+CD144+ endothelial cells and about 20-70% CD140b+CD271+ MSC-like cells.
[0188] In some embodiments, the endothelial cells are CD31+, CD 144+ and CD271+.
[0189] In some embodiments, the endothelial cells are about 70-100% CD146+ (e.g., about 70-95%, about 70-90%, about 70-80%, about 75-100%, about 75-95%, about 75-90%, about 80-100%, about 80-95%, about 80-90%, or about 90-100% CD146+, e.g., as analyzed by flow cytometry. In some embodiments, the endothelial cells are about 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or 100% CD146+ (e.g., as analyzed by flow cytometry).
[0190] In some embodiments, the endothelial cells are about 60-90% CXCR4+ (e.g., about 60-85%, about 60-80%, about 60-75%, about 60-70%, about 65-90%, about 70-90%, r27MEI 52993232v.l127206-11520about 70-85%, about 70-80%, about 80-90%, or about 75-90% CXCR4+, e.g., as analyzed by flow cytometry). In some embodiments, the endothelial cells are about 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, or 90% CXCR4+ (e.g., as analyzed by flow cytometry).
[0191] In some embodiments, the population of VPCs has an about 20-60% decrease in the expression (e.g., as analyzed by flow cytometry) of one or more proteins selected from the group consisting of CD34 and CD43 as compared to the population of intermediate VPCs (e.g., intermediate VPCs harvested on Day 6).
[0192] In some embodiments, the population of VPCs comprises CD31+CD144+ endothelial cells and MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0193] In some embodiments, the population of VPCs comprises about 40-90% CD31+CD144+ endothelial cells (e.g., about 40-85%, about 40-80%, about 50-90%, about 50-80%, about 60-90%, about 75-85%, or about 70-90% CD31+CD144+ endothelial cells, e.g., as analyzed by scRNA-seq). In some embodiments, the population of VPCs comprises about 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 71%, 72%, 73%, 74% 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90% CD31+CD144+ endothelial cells (e.g., as analyzed by scRNA-seq). In some embodiments, the population of VPCs comprises at least about 70%, 71%, 72%, 73%, 74% 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90% CD31+CD144+ endothelial cells (e.g., as analyzed by scRNA-seq).
[0194] In some embodiments, the population of VPCs comprises about 10-30% MEST+ALCAM+ MSC-like cells (e.g., about 10-25%, about 10-20%, about 20-30%, about 15-30%, or about 15-25% MEST+ALCAM+ MSC-like cells, e.g., as analyzed by scRNA-seq). In some embodiments, the population of VPCs comprises about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq). In some embodiments, the population of VPCs comprises less than about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0195] In some embodiments, the population of VPCs comprises about 70-90% CD31+CD144+ endothelial cells and about 10-30% MEST+AECAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).MEI 52993232v.l127206-11520
[0196] In some embodiments, the population of VPCs comprises about 75-85% CD31+CD144+ endothelial cells and about 15-25% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0197] In some embodiments, the population of VPCs comprises about 80% CD31+CD144+ endothelial cells and about 20% MEST+ALCAM+ MSC-like cells (e.g., as analyzed by scRNA-seq).
[0198] In some embodiments, the population of VPCs comprises endothelial cells that expressing one or more cell surface markers selected from the group consisting of CD31, CD 144, CD271, CD 146, and CXCR4. In some embodiments, the endothelial cells are CD31+, CD144+, and / or CD271+. In some embodiments, the endothelial cells are CXCR4+ and / or CD146+. In some embodiments, the endothelial cells are CD31+. CD144+. CD271+. CXCR4+, and CD 146+ .
[0199] In some embodiments, the endothelial cells are CD31+, CD144+ and CD271+.
[0200] In some embodiments, the endothelial cells are not CD31+, CD 144- and RUNX1+.
[0201] In some embodiments, the population of VPCs produced by the methods disclosed herein comprises less than about 1% (e.g., less than about 0.5%, 0.2%, or 0.1%) EPCAM+SOX17+ endoderm-like cells (e.g., as analyzed by scRNA-seq).
[0202] In some embodiments, the population of VPCs does not comprise undifferentiated pluripotent stem cells. In some embodiments, the population of VPCs produced by the methods disclosed herein does not comprise OCT4+NANOG+SOX2 undifferentiated pluripotent stem cells (e.g., as analyzed by scRNA-seq).
[0203] In some embodiments, the population of VPCs produced by the methods disclosed herein does not comprise OCT4+CDH2+ mesoderm cells (e.g., as analyzed by scRNA-seq).
[0204] In some embodiments, the endothelial population of VPCs has an about 80-130% (e.g., about 80-120%, about 90-130%, about 80-100%, about 100-130%, about 80-110%, about 90-110%, about 110-130%, about 90-120%) increase in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CAV1, ANXA1, CD59, IGFBP3 and ANGPT2 as compared to the endothelial population of intermediate VPCs (e.g. intermediate VPCs harvested on Day 6). In some embodiments, the endothelial population of VPCs has an about 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 100%, 102%, 104%, 106%, 108%, 110%, 112%, 114%, 116%, 118%, 120%, 122%, 124%, 126%, 128%, or 130% increase in the expression (e.g., as analyzed by scRNA-29MEI 52993232v.l127206-11520seq) of one or more genes selected from the group consisting of CAV1, ANXA1, CD59, IGFBP3 and ANGPT2 as compared to the endothelial population of intermediate VPCs.
[0205] In some embodiments, the endothelial population of VPCs has an about 25-75% (e.g., about 25-70%, about 30-75%, about 25-70%, about 25-60%, about 25-50%, about 50-75%, about 30-60%, about 40-70%, about 30-50%, or about 35-75%) decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of APOE, CD24 and DLK1 as compared to the endothelial population of intermediate VPCs (e.g. intermediate VPCs harvested on Day 6). In some embodiments, the endothelial population of VPCs has an about 25%, 27%, 29%, 31%, 33%, 35%, 37%, 39%, 41%, 43%, 45%, 47%, 49%, 51%, 53%, 55%, 57%, 59%, 61%, 63%, 65%, 67%, 69%, 71%, 73%, or 75% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of APOE, CD24 and DLK1 as compared to the endothelial population of intermediate VPCs.
[0206] In some embodiments, the endothelial population of VPCs has an about 20-50% (e.g., about 25-50%, about 30-50%, about 20-45%, about 20-40%, about 20-30%, about 30-40%, about 20-40%, about 40-50%, or about 30-50%) decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CD34, RUNX1, CD44 and SPN as compared to the endothelial population of intermediate VPCs (e.g., intermediate VPCs harvested on Day 6). In some embodiments, the endothelial population of VPCs has an about 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, or 50% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CD34, RUNX1, CD44 and SPN as compared to the endothelial population of intermediate VPCs.
[0207] In some embodiments, the endothelial population of VPCs has an about 40-90% (e.g., about 40-80%, about 40-70%, about 40-60%, about 40-50%, about 50-90%, about 50-80%, about 50-70%, about 60-90%, about 60-80%, about 70-90%, or about 80-90%) increase in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of CXCR4, EFNB2, and GJA4 as compared to the endothelial population of intermediate VPCs (e.g., intermediate VPCs harvested on Day 6). In some embodiments, the endothelial population of VPCs has an about 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, or 90% increase in the expression (e.g., as analyzed by scRNA-seq) of one or more30MEI 52993232v.l127206-11520genes selected from the group consisting of CXCR4, EFNB2, and GJA4 as compared to the endothelial population of intermediate VPCs.
[0208] In some embodiments, the MSC-like population of VPCs has an about 30-60% (e.g., about 35-60%, about 35-50%, about 40-60%, about 40-50%, about 50-60%, about 30-50%, about 30-55%, about 30-45%, about 45-60%, about 30-40%, or about 35-55%) decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of ACTC1, BAMBI, HANDI, COL1A1, and COL1A2 as compared to the MSC-like population of intermediate VPCs (e.g., intermediate VPCs harvested on Day 6). In some embodiments, the MSC-like population of VPCs has an about 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, or 60% decrease in the expression (e.g., as analyzed by scRNA-seq) of one or more genes selected from the group consisting of ACTC1, BAMBI, HANDI, COL1A1, and COL1A2 as compared to the MSC-like population of intermediate VPCs.
[0209] In some embodiments, the population of VPCs secrets an increased level of one or more proteins selected from the group consisting of CCL2, FGF2, ANGPT1, AGNPT2, SDFla, HGF, Follistatin, EGF, and ANGPTL4 (e.g., as analyzed by ELISA) as compared to the population of intermediate VPCs (e.g., intermediate VPCs harvested on Day 6).
[0210] In one embodiment, the VPCs are genetically modified. The VPCs may be genetically modified such that they express gene products that are believed to or are intended to promote the therapeutic response(s) provided by the cells. For example, the VPCs may be genetically modified to express and / or a heterologous protein from the cells such as vascular endothelial growth factor (VEGF) and its isoforms, fibroblast growth factor (FGF, acid and basic), angiopoietin-1 and other angiopoietins, erythropoietin, hemoxygenase, transforming growth factor-a (TGF-a), transforming growth factor-P (TGF-P) or other members of the TGF-P super family including BMPs 1, 2, 4, 7 and their receptors MBPR2 or MBPR1, hepatic growth factor (scatter factor), hypoxia inducible factor (HIF), endothelial nitric oxide synthase, prostaglandin I synthase, Krupple-like factors (KLF-2, 4, and others), and any other heterologous protein useful for promoting a therapeutic response against vascular diseases.IV. Pharmaceitucal Compositions
[0211] The present invention provides pharmaceutical compositions comprising the VPCs described herein. Pharmaceutical compositions comprising the VPCs of the invention may be formulated with a pharmaceutically acceptable carrier. For example, VPCs of the31MEI 52993232v.l127206-11520invention may be administered alone or as a component of a pharmaceutical formulation, wherein the VPCs may be formulated for administration in any convenient way for use in medicine.
[0212] Suitable pharmaceutically acceptable carriers for the present disclosure include those conventionally used, e.g., a cryopreservation media, water, saline, aqueous dextrose, lactose, Ringer's solution, a buffered solution, hyaluronan, or glycols. In some embodiments, the pharmaceutically acceptable carrier is a cryopreservation media, e.g., comprising about 5-10% DMSO.
[0213] In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel, e.g., a biomaterial or a hydrogel derived from hyaluronic acid, chitosan, collagen, elastin, fibrin, fibrinogen, gelatin, alginate, cellulose, silk, fibrin, polyacrylic acid (PAA), polyethylene glycol (PEG), polylactic-co-glycolic acid, and / or Pluronic F-127. In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from homogenously deacetylated chitin (HDC). In some embodiments, the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from crystalline cellulose / carmellose sodium (CMC-Na).
[0214] Other exemplary carriers or excipients are described, for example, in Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N. Y.; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, N. Y.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY; and Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, N. Y.
[0215] The pharmaceutical compositions comprising the VPCs can be formulated in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions selected from the group consisting of dispersions, suspensions, emulsions, sterile powders optionally reconstituted into sterile injectable solutions or dispersions just prior to use, antioxidants, buffers, bactericides, solutes or suspending and thickening agents.
[0216] Exemplary pharmaceutical compositions of the present disclosure may be any formulation suitable for use in treating a human patient, such as a patient suffering from a vascular disease or disorder. In one embodiment, the pharmaceutical composition32MEI 52993232v.l127206-11520comprising VPCs are formulated as an injectable material, e.g., a material suitable for intravenous, intramuscular, intradermal, subcutaneous, or or intraocular injection. The pharmaceutical composition comprising the VPCs may be administered in a buffered solution at a physiological pH, further containing an osmotically active agent maintaining the solution at a physiologically osmolality. Other reagents known in art can also be used to formulate the pharmaceutical composition. In one embodiment, the buffers or solutions used to formulate the pharmaceutical compositions are sterilized before use.
[0217] The pharmaceutical compositions comprising the VPCs used in the methods described herein may be delivered in a suspension, gel, colloid, slurry, or mixture. Also, at the time of delivery, cryopreserved VPCs may be resuspended with commercially available balanced salt solution to achieve the desired osmolality and concentration for administration by injection (e.g., bolus or intravenous). The pharmaceutical compositions comprising the VPCs may be delivered, e.g., via one or more injections, to the subject in a mixture with a durable inert matrix. Durable inert matrix such as hydrogels - natural or synthetic waterinsoluble polymers - could provide scaffolds for the cell’s growth and expansion at the site of administration. Other suitable materials known in the art that provide durable inert matrix scaffolds for cell growth and expansion can also be used in the methods described herein.
[0218] The pharmaceutical compositions comprising the VPCs may be delivered by one or more injections, e.g., via a syringe. Alternatively, the pharmaceutical compositions comprising the VPCs may be delivered by other suitable methods known in the art. Suitable delivery methods may further facilitate the growth and survival of the VPCs and prevent cell loss at the site of administration. In certain embodiments, appropriate delivery methods help retain the VPCs at the site of the administration and provide optimal environment for cell growth. Accordingly, the pharmaceutical compositions comprising the VPCs can also be formulated into, e.g., a hydrogel tube, a hydrogel sheet, a bioengineered patch made from natural or artificial materials, or a cell sheet that provides sufficient support for the VPCs in the pharmaceutical composition. In one embodiment, the pharmaceutical compositions comprising the VPCs are delivered in the form of a hydrogel tube. In one embodiment, the pharmaceutical compositions comprising the VPCs are delivered in the form of a hydrogel sheet. In one embodiment, the pharmaceutical compositions comprising the mo- VPCs are delivered in the form of a bioengineered patch. In one embodiment, the pharmaceutical compositions comprising the VPCs are delivered in the form of a cell sheet. Any other33MEI 52993232v.l127206-11520suitable methods known in the art can also be used in the delivery of the pharmaceutical compositions described herein.
[0219] Pharmaceutical compositions typically should be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as a solution, microemulsion, liposome, or other ordered structure. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be desirable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the soluble factors may be administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
[0220] One aspect of the invention relates to a pharmaceutical composition suitable for use in a mammalian patient, e.g., a human patient, comprising at least 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, or 1013VPCs and a pharmaceutically acceptable carrier.Concentrations for administration of pharmaceutical preparations of VPCs may be at any amount that is effective and, for example, substantially free of PSCs. For example, the pharmaceutical compositions may comprise the numbers and types of VPCs described herein. In a particular embodiment, the pharmaceutical compositions of VPC comprise about IxlO4to about IxlO5, about IxlO5to about IxlO6, about 1 x 106to about 1 x 107, about 1 x 107to about I x lO8, about 1 x 108to about I x lO9, about 1 x 109to about 1 x 1010, about I x lO10to about I x lO11, about 1 x 1011to about 1 x 1012, or about I x lO12to about I x lO13of the VPCs for systemic administration to a host in need thereof or about 1 x 104to about 1 x 105, about 1 x 105to about 1 x 106, 1 x 106to about 1 x 107, about 1 x 107to about 1 x 108, about34MEI 52993232v.l127206-115201 x 108to about 1 x 109, about 1 x 109to about 1 x IO10, about 1 x IO10to about 1 x 1011, about 1 x 1011to about 1 x 1012, or about 1 x 1012to about 1 x 1013of said VPCs for local administration to a host in need thereof.V. Methods of Treatment
[0221] The VPCs and pharmaceutical compositions comprising the VPCs of the invention are useful for treating vascular diseases and / or ameliorate related symptoms. Thus, the present invention provides a method of treating a vascular disease in a subject by administering to a subject a composition comprising VPCs of the invention.
[0222] Vascular disease refers to any abnormal condition or injury of the heart, lungs, and / or blood vessels (arteries, veins, and capillaries). Vascular disease includes, but is not limited to, diseases, disorders, and / or injuries of the pericardium (i.e., pericardium), heart valves (e.g., incompetent valves, stenosed valves, rheumatic heart disease, mitral valve prolapse, aortic regurgitation), myocardium (coronary artery disease, myocardial infarction, heart failure, ischemic heart disease, angina) blood vessels (e.g., arteriosclerosis, aneurysm) or veins (e.g., varicose veins, hemorrhoids). Vascular disease, as used herein also includes, but is not limited to, coronary artery diseases (e.g., arteriosclerosis, atherosclerosis, and other diseases or injuries of the arteries, arterioles and capillaries or related complaint), myocardial infarction (e.g., acute myocardial infarction), organizing myocardial infarct, ischemic heart disease, arrhythmia, left ventricular dilatation, emboli, heart failure, congestive heart failure, subendocardial fibrosis, left or right ventricular hypertrophy, myocarditis, chronic coronary ischemia, dilated cardiomyopathy, restenosis, arrhythmia, angina, hypertension (e.g., pulmonary hypertension, glomerular hypertension, portal hypertension), myocardial hypertrophy, peripheral arterial disease, intermittent claudication, critical limb ischemia, diabetic foot ulcer, cerebrovascular disease, renal artery stenosis, aortic aneurysm, pulmonary heart disease, cardiac dysrhythmias, inflammatory heart disease, congenital heart disease, rheumatic heart disease, diabetic vascular diseases, diabetic retinopathy, Buerger's disease, Reynaud's syndrome, acute limb ischemia, endothelial lung injury diseases (e.g., acute lung injury (ALT)), and acute respiratory distress syndrome (ARDS)). Vascular diseases may also result from congenital defects, genetic defects, environmental influences (e.g., dietary influences, lifestyle, stress, etc.), and other defects or influences.
[0223] In one embodiment, the vascular disease is an ischemic disease, such as critical limb ischemia (CLI, also known as critical limb-threatening ischemia (CLTI)). In one35MEI 52993232v.l127206-11520embodiment, the vascular disease is a diabetic vascular disease. In some embodiments, the vascular disease is diabetic retinopathy. In one embodiment, the vascular disease is a peripheral artery disease (PAD). In one embodiment, the vascular disease is intermittent claudication. In one embodiment, the vascular disease is acute limb ischemia. In one embodiment, the vascular disease is Buerger’s disease. In one embodiment, the vascular disease is diabetic foot ulcer (DFU). In one embodiment, the vascular disease is acute respiratory distress syndrome (ARDS). In one embodiment, the vascular disease is acute lung injury (ALI). In one embodiment, the vascular disease is pulmonary arterial hypertension (PAH).
[0224] The VPCs of the invention may be useful to treat the symptoms of vascular diseases. For example, the VPCs may be used for treating a symptom of myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, dilated cardiomyopathy, restenosis, coronary artery disease, heart failure, arrhythmia, angina, atherosclerosis, hypertension, critical limb ischemia, peripheral vascular disease, pulmonary hypertension, or myocardial hypertrophy. Treatment of one or more symptoms of the vascular disease may confer a clinical benefit, such as a reduction in one or more of the following symptoms: shortness of breath, fluid retention, headaches, dizzy spells, chest pain, left shoulder or arm pain, and ventricular dysfunction.
[0225] In some embodiments, treatment of one or more symptoms of critical limb ischemia may confer a clinical benefit, such as a reduction in one or more of the following symptoms: pain or numbness in the feet, absent or diminished pulse in the legs or feet, and dry gangrene of the legs or feet.
[0226] In some embodiments, treatment of one or more symptoms of diabetic vascular disease may confer a clinical benefit, such as a reduction in one or more of the following symptoms: blurry vision, floaters, swelling of the face, fingers, or toes or weight gain, and foot ulcers caused by blood vessel narrowing in the feet.
[0227] The VPCs of the invention may exhibit certain properties that contribute to reducing and / or minimizing damage and promoting vascular repair and regeneration following damage. These include, among other things, the ability to synthesize and secrete growth factors stimulating new blood vessel formation, the ability to synthesize and secrete growth factors stimulating cell survival and proliferation, the ability to proliferate and differentiate into cells directly participating in new blood vessel formation, the ability to36MEI 52993232v.l127206-11520engraft damaged myocardium and inhibit scar formation (collagen deposition and crosslinking), and the ability to proliferate and differentiate into cells of the vascular lineage.
[0228] In an embodiment, the VPCs of the invention are capable of vascular repair. In one embodiment, the VPCs contribute to post-injury progenitor cell replenishment under normal conditions. In another embodiment, the VPCs of the invention are capable of homing to the site of vascular injury and facilitating re-endothelialization and preventing neointimal formation. Accordingly, the VPCs of the present invention may be used to treat vascular tissue damaged due to injury or inflammation or disease. In some embodiments, the VPCs of the invention are capable of increasing the blood flow, collateralization, arteriogenesis, or capillary density in the subject. In some embodiments, the VPCs of the invention are capable of promoting the angiogenesis and / or vasculogenesis in the subject. In some embodiments, the VPCs of the invention are capable of reducing the ischemic severity in the subject. Other physical and functional changes in the subject can also be measured and quantified to determine the efficacy of the methods of treatment of vascular diseases.
[0229] Accordingly, in some aspects, disclosed herein is a method of increasing blood flow in a subject suffering from, or suspected of suffering from, a vascular disease, wherein the method comprises administering to the subject the composition disclosed herein, or the pharmaceutical composition disclosed herein, thereby increasing the blood flow in the subject.
[0230] In some aspects, disclosed herein is a method of increasing capillary density in a subject suffering from, or suspected of suffering from, a vascular disease, wherein the method comprises administering to the subject the composition disclosed herein, or the pharmaceutical composition disclosed herein, thereby increasing the capillary density in the subject.
[0231] In some aspects, disclosed herein is a method of reducing blood pressure in a subject suffering from, or suspected of suffering from, a vascular disease, wherein the method comprises administering to the subject the composition disclosed herein, or the pharmaceutical composition disclosed herein, thereby reducing the blood pressure in the subject.
[0232] In some aspects, disclosed herein is a method of promoting wound healing in a subject, wherein the wound comprises an impaired vasculature and wherein the method comprises administering to the subject the composition of any preceding aspect, or the37MEI 52993232v.l127206-11520pharmaceutical composition of any preceding aspect, thereby promoting wound healing in the subject.
[0233] The effects of treatment with VPCs of the invention may be demonstrated by, but not limited to, one of the following clinical measures: increased heart ejection fraction, decreased rate of heart failure, decreased infarct size, decreased associated morbidity (pulmonary edema, renal failure, arrhythmias) improved exercise tolerance or other quality of life measures, and decreased mortality. The effects of cellular therapy may be evident over the course of days to weeks after the procedure. However, beneficial effects may be observed as early as several hours after the procedure, and may persist for several years.
[0234] The subject being treated with VPCs of the invention according to the methods described herein will usually have been diagnosed as having, suspected of having, or being at risk for, a vascular disease. The vascular disease may be diagnosed and / or monitored, typically by a physician using standard methodologies. “Subject” and “patient” are used interchangeably herein and refers to any vertebrate, including, mammals, rodents, and nonmammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc. In a specific embodiment, the subject is primate. In another embodiment, the subject is a human.
[0235] In some embodiments, the methods of the invention may be practiced in conjunction with existing vascular therapies to effectively treat a vascular disease. The methods and compositions of the invention include concurrent or sequential treatment with non-biologic and / or biologic drugs. Non-limiting examples of non-biologic and / or biologic drugs include analgesics, such as nonsteroidal anti-inflammatory drugs, opiate agonists and salicylates; anti-infective agents, such as antihelmintics, antianaerobics, antibiotics, aminoglycoside antibiotics, antifungal antibiotics, cephalosporin antibiotics, macrolide antibiotics, miscellaneous P-lactam antibiotics, penicillin antibiotics, quinolone antibiotics, sulfonamide antibiotics, tetracycline antibiotics, antimycobacterials, antituberculosis antimycobacterials, antiprotozoals, antimalarial antiprotozoals, antiviral agents, anti-retroviral agents, scabicides, anti-inflammatory agents, corticosteroid anti-inflammatory agents, antipruritics / local anesthetics, topical anti-infectives, antifungal topical anti-infectives, antiviral topical anti-infectives; electrolytic and renal agents, such as acidifying agents, alkalinizing agents, diuretics, carbonic anhydrase inhibitor diuretics, loop diuretics, osmotic diuretics, potassium- sparing diuretics, thiazide diuretics, electrolyte replacements, and uricosuric agents; enzymes, such as pancreatic enzymes and thrombolytic enzymes;38MEI 52993232v.l127206-11520gastrointestinal agents, such as antidiarrheals, gastrointestinal anti-inflammatory agents, gastrointestinal anti-inflammatory agents, antacid anti-ulcer agents, gastric acid-pump inhibitor anti-ulcer agents, gastric mucosal anti-ulcer agents, H2-blocker anti-ulcer agents, cholelitholytic agent's, digestants, emetics, laxatives and stool softeners, and prokinetic agents; general anesthetics, such as inhalation anesthetics, halogenated inhalation anesthetics, intravenous anesthetics, barbiturate intravenous anesthetics, benzodiazepine intravenous anesthetics, and opiate agonist intravenous anesthetics; hormones and hormone modifiers, such as abortifacients, adrenal agents, corticosteroid adrenal agents, androgens, antiandrogens, immunobiologic agents, such as immunoglobulins, immunosuppressives, toxoids, and vaccines; local anesthetics, such as amide local anesthetics and ester local anesthetics; musculoskeletal agents, such as anti-gout anti-inflammatory agents, corticosteroid antiinflammatory agents, gold compound anti-inflammatory agents, immunosuppressive antiinflammatory agents, nonsteroidal anti-inflammatory drugs (NSAIDs), salicylate antiinflammatory agents, minerals; and vitamins, such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, and vitamin K.
[0236] The VPCs or pharmaceutical compositions of the instant invention may be administered systemically or locally. The VPCs or pharmaceutical compositions may be administered using modalities known in the art including, but not limited to, injection via intravenous, intracranial, intramuscular, intradermal, subcutaneous, intraocular, intraperitoneal, or other routes of administration, or local implantation, dependent on the particular pathology being treated. In one embodiment, the VPCs or pharmaceutical compositions are administered intramuscularly, intradermally, subcutaneously, or intraocularly. In one embodiment, the VPCs or pharmaceutical compositions are administered peri-arterially.
[0237] In some embodiments, the VPCs or pharmaceutical compositions of the invention may be administered by several routes including systemic administration by venous or arterial infusion (including retrograde flow infusion) or by direct injection into the heart or peripheral tissues. Systemic administration, particularly by peripheral venous access, has the advantage of being minimally invasive relying on the natural perfusion of the heart and the ability of the vascular endothelial progenitors to target the site of damage. Cells may be injected in a single bolus, through a slow infusion, or through a staggered series of applications separated by several hours or, provided cells are appropriately stored, several days or weeks. Cells may also be applied by use of catheterization such that the first pass of39MEI 52993232v.l127206-11520cells through the heart is enhanced by using balloons to manage myocardial blood flow. As with peripheral venous access, cells may be injected through the catheters in a single bolus or in multiple smaller aliquots. Cells may also be applied directly to the myocardium by epicardial injection. This could be employed under direct visualization in the context of an open-heart procedure (such as a Coronary Artery Bypass Graft Surgery) or placement of a ventricular assist device. Catheters equipped with needles may be employed to deliver cells directly into the myocardium in an endocardial fashion which would allow a less invasive means of direct application.
[0238] In one embodiment, the route of delivery includes intravenous delivery through a standard peripheral intravenous catheter, a central venous catheter, or a pulmonary artery catheter. In other embodiments, the cells may be delivered through an intracoronary route to be accessed via currently accepted methods. The flow of cells may be controlled by serial inflation / deflation of distal and proximal balloons located within the patient's vasculature, thereby creating temporary no-flow zones which promote cellular engraftment or cellular therapeutic action. In another embodiment, cells may be delivered through an endocardial (inner surface of heart chamber) method which may require the use of a compatible catheter as well as the ability to image or detect the intended target tissue. Alternatively, cells may be delivered through an epicardial (outer surface of the heart) method. This delivery may be achieved through direct visualization at the time of an open-heart procedure or through a thoracoscopic approach requiring specialized cell delivery instruments. Furthermore, cells could be delivered through the following routes, alone, or in combination with one or more of the approaches identified above: subcutaneous, intramuscular, intra-tracheal, sublingual, retrograde coronary perfusion, coronary bypass machinery, extracorporeal membrane oxygenation (ECMO) equipment and via a pericardial window.
[0239] In some embodiments, the VPCs or pharmaceutical compositions of the instant invention may be administered via local implantation, wherein a delivery device is utilized. Delivery devices of the instant invention are biocompatible and biodegradable. A delivery device of the instant invention can be manufactured using materials selected from the group comprising biocompatible fibers, biocompatible yarns, biocompatible foams, aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, tyrosine derived polycarbonates, poly (iminocarbonates), poly orthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, biopolymers; homopolymers and copolymers of lactide, glycolide,40MEI 52993232v.l127206-11520epsilon-caprolactone, para-dioxanone, trimethylene carbonate; homopolymers and copolymers of lactide, glycolide, epsilon-caprolactone, para-dioxanone, trimethylene carbonate, fibrillar collagen, non-fibrillar collagen, collagens not treated with pepsin, collagens combined with other polymers, growth factors, extracellular matrix proteins, biologically relevant peptide fragments, hepatocyte growth factor, platelet-derived growth factors, platelet rich plasma, insulin growth factor, growth differentiation factor, vascular endothelial cell-derived growth factor, nicotinamide, glucagon like peptides, tenascin-C, laminin, anti-rejection agents, analgesics, anti-oxidants, anti-apoptotic agents antiinflammatory agents and cytostatic agents.
[0240] The particular treatment regimen, route of administration, and adjuvant therapy may be tailored based on the particular pathology, the severity of the pathology, and the patient’s overall health. Administration of the VPCs or pharmaceutical compositions may be effective to reduce the severity of the manifestations of a pathology or and / or to prevent further degeneration of the manifestation of a pathology.
[0241] A treatment modality of the present invention may comprise the administration of a single dose of VPCs or pharmaceutical compositions. Alternatively, treatment modalities described herein may comprise a course of therapy where VPCs or pharmaceutical compositions are administered multiple times over some period of time. Exemplary courses of treatment may comprise weekly, biweekly, monthly, quarterly, biannually, or yearly treatments. Alternatively, treatment may proceed in phases whereby multiple doses are required initially (e.g., daily doses for the first week), and subsequently fewer and less frequent doses are needed.
[0242] In one embodiment, the VPCs or pharmaceutical compositions are administered to a patient one or more times periodically throughout the life of a patient. In a further embodiment of the instant invention, the VPCs or pharmaceutical compositions are administered once per year, once every 6-12 months, once every 3-6 months, once every 1-3 months, or once every 1-4 weeks. Alternatively, more frequent administration may be desirable for certain conditions or disorders. In one embodiment, the VPCs or pharmaceutical compositions are administered via a device once, more than once, periodically throughout the lifetime of the patient, or as necessary for the particular patient and patient’s pathology being treated. Similarly contemplated is a therapeutic regimen that changes over time. For example, more frequent treatment may be needed at the outset (e.g.,41MEI 52993232v.l127206-11520daily or weekly treatment). Over time, as the patient’s condition improves, less frequent treatment or even no further treatment may be needed.VI. Kit
[0243] The present invention also provides kits comprising, in one or more separate compartments, the VPCs or the pharmaceutical compositions of the invention. The kits may further comprise additional ingredients, e.g., gelling agents, emollients, surfactants, humectants, viscosity enhancers, emulsifiers in one or more compartments. The kits may optionally comprise instructions for formulating the VPCs or the pharmaceutical compositions for diagnostic or therapeutic applications. The kits may also comprise instructions for using the components, either individually or together, in the therapy of vascular disorders and / or diseases. In one embodiment, the kit of the present invention includes a syringe for the injection of the pharmaceutical compositions comprising the VPCs.
[0244] In some embodiments, the present invention provides kits comprising the VPCs of the invention along with reagents for selecting, culturing, expanding, sustaining, and / or transplanting the VPCs. Representative examples of cell selection kits, culture kits, expansion kits, transplantation kits are known in the art. Cells may also be enriched in the sample by using positive selection, negative selection, or a combination thereof for expression of gene products thereof.
[0245] The present invention is further illustrated by the following examples, which are not intended to be limiting in any way. The entire contents of all references, patents and published patent applications cited throughout this application, as well as the Figures, are hereby incorporated herein by reference.EXAMPLESExample 1: Generation of Vascular Progenitor Cells (VPCs).
[0246] Vascular progenitor cells (VPCs) were generated from human induced pluripotent stem cells (iPSCs) as shown in FIG. 1. Briefly, iPSCs were cultured in StemFit medium. To plate iPSCs for differentiation (Day -1), StemFit medium was removed and plates was washed with DMEM / F12 (Gibco) or D-PBS. Enzyme-free Gibco® Cell Dissociation Buffer (CDB) was added to each well. The plates were incubated inside a normoxic CO2 incubator (5% CO2 / 20% O2) until the cells showed a detached morphology. CDB was then carefully42MEI 52993232v.l127206-11520removed by pipetting without disturbing loosely attached cells. Cells were collected by adding StemFit medium to each well and collected in collection tubes. The remaining cells in the wells were washed gently with StemFit medium and transferred to the collection tubes. Tubes were centrifuged and the culture medium was removed. Cells were seeded on a collagen IV-coated plate at a final density of 5,000-10,000 cells / cm2in StemFit medium containing 10 pM Rock inhibitor (Y-27632). The plates were placed in the normoxic incubator overnight.
[0247] The next day (Day 0), the StemFit / Y-27632 medium was gently removed from the plate and replaced with a VPC differentiation medium (cGMP StemSpan- AOF medium with 25 ng / mL BMP4, 50 ng / mL VEGF, and 50 ng / mL FGF2). The plates were incubated in a hypoxia incubator (5% CO2 / 5% O2) for 6 days.
[0248] On Day 2, and D4, the medium was aspirated and fresh VPC differentiation medium was added to each plate.
[0249] On Day 6, intermediate VPC cells (D6 VPCs) were collected, frozen at < -70°C for at least 24 hrs, and thawed. D6 VPCs were subsequently replated on a collagen IV-coated plate at a final density of 28,000-172,000 cells / cm2in an endothelial expansion medium (StemDiff Endothelial Expansion medium with 12 g / mL heparin and 1 pg / mL hydrocortisone). The plates were then placed in a hypoxia incubator (5% CO2 / 5% O2) for 4 days. Alternatively, the plates could also be placed in a normoxia incubator (5% CO2 / 20% O2) for 4 days.
[0250] On Day 8, the medium was aspirated and fresh endothelial expansion medium was added to each plate.
[0251] On Day 10, VPCs (D10 VPCs) were harvested for in vitro and in vivo testing. The medium was aspirated from each plate and the plates were washed by adding D-PBS (Gibco) and aspirating the D-PBS. CTS TrypLE Select (Gibco) was added to each plate and incubated for 3-5 min in a normoxic CO2 incubator (5% CO2 / 20% O2). The cells were pipetted and then strained through a 30 pM cell strainer and transferred into a collection tube. The tubes were centrifuged at 120-250xg for 5 min and counted. After counting, the cells were resuspended with Freezing medium (CryoStorlO, StemCell Technologies ) to create frozen stocks.
[0252] Additional endothelial expansion medium listed in Table 1 were also tested and yield D10 VPCs. Endothelial expansion medium with additional small molecules, such as Forskolin, DAPT and SB431542, each at 5 pM, were also tested. It has been shown that43MEI 52993232v.l127206-11520addition of Forskolin, DAPT and SB431542 further increases the endothelial cell population (CD31+, CD34+) of the DIO VPC, and / or decreases the mesenchymal population (CD140b+, CD271+) and the blood population (CD43+) (data not provided).Table 1. Media permutations that are tested.1 2 3 4 5 6 7 8 9 10Stem StemMA StemMA Stemsp Stem diffH / Stemdif StemDif C S C s Stemsp anH / H StemL Base diff HC / R fH / HC / fH / HC / H / HC / B H / HC / BV anH / H C / BVF ine II / Condition (H) H / HC I SB43 FBS VF F / FBS C / BVF / FBS BVF Base StemL media Stem Diff Stem MACs Stem span ine II Heparin12 pg / mL X X X X X X X X X Hydrocortisone 1pg / mL X X X X X X X XBMP425ng / mL X X X X X bFGF 50ng / mL X X X X X VEGF 50ng / mL X X X X X 5% FBS X X XRIY27632(10 pM) XSB431542(10 pM) XExample 2: Transcriptional Characterization of DIO VPC and D6 VPC
[0253] Single cell RNA-sequencing analysis was performed to compare VPCs harvested at Day 10 (DIO VPC), the intermediate VPCs harvested at Day 6 (D6 VPC), human umbilical vein endothelial cells (HUVEC), and undifferentiated pluripotent stem cells (PSC).
[0254] Unsupervised clustering revealed different clusters among the cell types tested. As shown in FIG. 2A, undifferentiated PSCs clustered distinctly from D10 VPC, D6 VPC and HUVEC, as expected. Notably, D10 VPC clustered differently from D6 VPC, suggesting that the cell population of D10 VPC is different from the cell population of D6 VPC.
[0255] Analysis of different subpopulation markers further confirms that D10 VPC represents a distinct cell population from the intermediate D6 VPC (FIG. 2C). In particular, D6 VPC was shown to have multiple subpopulations, including endoderm-like cells (EPCAM+SOX17+), early mesoderm cells (OCT4+CDEE2+), MSC-like cells MEST+ALCAM+), myeloid / endothelial progenitor cells (CD31+CD144-RUNX1+), and endothelial cells (CD31+CD144+), while D10 VPC is a population of more mature and44MEI 52993232v.l127206-11520enriched cells with essentially 2 subpopulations that are MSC-like cells (MEST+ALCAM+) and endothelial cells (CD31+CD144+). FIG. 2B shows the combined MSC-like subpopulations and CD31+ populations in DIO VPC, D6 VPC, HUVEC and PSC. Even within the CD31+ cells, D6 VPC have distinct subpopulations (CD31+CD144+ and the CD31+CD144-RUNX1+ endothelial / myeloid progenitor population), whereas these subpopulations are not present in Day 10 VPC (FIG. 2C).
[0256] Table 2 provides the fraction of each subpopulation in DIO VPC, D6 VPC, HUVEC and PSC.Table 2. Fraction of Different Subpopulations in DIO VPC, D6 VPC, HUVEC and PSC.PSC Endoderm-like Mesodem MSC-like EC HUVEC 0 0 0 0.2 99.8 PSC 99.5 0 0 0.3 0.2 D6 VPC 0.2 2.2 2.0 63.2 32.4 D10 VPC 0 0.1 0 19.5 80.4Comparison of Endothelial Cell Subpopulation within DIO VPC and D6 VPC
[0257] Comparison of the endothelial cell (EC) subpopulation within the D10 VPC and D6 VPC was also performed. Genes that are differentially expressed within the D6 VPC EC cluster versus the D10 VPC EC cluster were identified (FIG. 3A), and the average log2 fold change was shown on the X-axis, and the absolute difference in percent of expressing cells was shown on the Y-axis. As shown in FIGs. 3A-3C, angiogenic / EC maturation factors, and anti-inflammatory-related genes (e.g., ANGPT2, CAV1, IGFBP3, ANXA1 and CD59) were upregulated in D10 VPC EC as compared to D6 VPC EC (e.g., about 96% increase for CAV1, about 122% increase for ANXA1, about 89% increase for CD59, about 103% increase for IGFBP3, and about 112% increase for ANGPT2), whereas primitive / early stem cell or progenitor markers (e.g., DLK1, CD24 or APOE) were down-regulated in D10 VPC EC (e.g., about 58% decrease for APOE, about 57% decrease for CD24, and about 56% decrease for DLK1). In addition, expression of early EC transcripts presented in D6 VPC EC (e.g., PECAM1, CD34, RUNX1, CDH5, CD44 and SPN) was shown to be reduced in D10 VPC EC (e.g., about 31% decrease in CD34, about 22% decrease in RUNX1) (FIG. 3D). Expression levels of arterial endothelial markers (e.g., EFNB2, CXCR4 or GJA4) and venous endothelial markers (e.g., EPHB4, NR2F2, or NRP2) were also evaluated. FIG. 3E shows that D10 VPC EC display greater arterial endothelial markers (e.g., about 48% increase in CXCR4, about 49% increase in EFNB2, and about 80% increase in GJA4).45MEI 52993232v.l127206-11520Comparison of MSC-like Cell Subpopulation within DIO VPC and D6 VPC
[0258] Comparison of the MSC-like cell subpopulation within the DIO VPC and D6 VPC was also performed. Genes that are differentially expressed within the D6 VPC MSC-like cluster and the DIO VPC MSC-like cluster were identified. As shown in FIGs. 4A-4B, DIO VPC MSC-like cluster shows a lower expression of typical D6 MSC-like transcripts, such as BAMBI, ACTC1, COL3A1, HAND1, ALCAM, COL1A1, or COL1A2 (e.g., about 54% decrease in ACTC1, about 50% decrease in BAMBI, about 40% decrease in HAND1, about 33% decrease in COL1A1, and about 47% decrease in COL1A2), but expresses more endothelial or pro-angiogenic genes (e.g., CAV1, GJA4, or ANGPT2).
[0259] Taken together, single cell RNA sequencing analysis demonstrates that D10 VPC represents a distinct cell population from the intermediate D6 VPC. Multiple subpopulations were observed in D6 VPC, while D10 VPC only has 2 subpopulations (MSC-like and EC). Notably, there are no undifferentiated pluripotent cells and mesoderm cells in the D10 VPC population. Furthermore, single cell RNA sequencing analysis confirms the differences within each subpopulation, wherein D10 VPC EC expresses more pro-angiogenic genes and less early EC transcripts than D6 VPC EC, and D10 VPC MSC-like cells also express more endothelial transcripts and less MSC markers seen in D6 VPC MSC-like subpopulation. Accordingly, these data suggest that D10 VPC represents a more mature group of cell population than D6 VPC.Example 3: Surface Protein Characterization of D10 VPC and D6 VPC
[0260] Cell surface markers were analyzed for D10 VPC and D6 VPC by flow cytometry using a SONY analyzer. HUVEC cells were used as a positive control and undifferentiated PSC were used as a negative control. As shown in FIG. 5A, D6 VPC and D10 VPC have different cell surface markers and represent different cell types.
[0261] Specifically, PDPN was the identity marker for D6 VPC, however, only less than 20% D10 VPC express PDPN (FIG. 5B). Similarly, greater than 70% of D10 VPC express CD271, but a much less percentage of D6 VPC express CD271.Comparison of Endothelial Cell Subpopulation within D10 VPC and D6 VPC
[0262] Comparison of the endothelial cell (EC) subpopulation within the D10 VPC and D6 VPC was also performed by flow cytometry. As shown in FIG. 5C, the D10 VPC46MEI 52993232v.l127206-11520protocol increases the maturity of its EC subpopulation, with a lower CD34+ progenitor ECs and an increase in the arterial CXCR4+ fraction of ECs.
[0263] The DIO VPC EC is a unique and rare subpopulation of endothelial cells which not only express bona fide endothelial markers (CD31 and CD 144), but also express stromal markers (CD271) (FIG. 5D and Table 3).Table 3. Percentage of cells within DIO VPC.AVG SD (% Range (Min-Max,N = 11 Cells) % Cells) Cell Type CD31+CD140b- 53.6+11 38.9-79 Endothelial CD31+CD140b+ (CD271+) 14+4.8 6.61-21.5 Perivascular CD31-CD271+ (CD140b+) 29.8+8.4 13.2-41.9 MesenchymalCD31-SSEA5+ / TRA-1-60+ 0.1+0.1 0.028-0.4 Residual PSC-likeExample 4. Protein Secretion Characterization of DIO VPC and D6 VPC.
[0264] Protein secretion profile was analyzed and compared between DIO VPC and D6 VPC by ELISA. Bone-marrow derived MSC (BM-MSC) was used as a control.
[0265] Briefly, VPCs were plated at 52M / cm2in Complete Vascullife media in fibronectin (FN)-coated 6-well plates and incubated in normoxia for 24 hrs. After 24 hrs, cells were washed with PBS, and media was changed to Vasculife media without VEGF, FGF2, or FBS. Cells were cultured for 48 hrs in either 5% or 20% O2. Media was collected, centrifuged, and supernatant was stored for future analysis at -80°C. Individual analytes were assessed by ELISA in technical duplicate. Data is mean + SEM, n = 2-6 biological replicates.
[0266] As shown in FIGS. 6A-6C, D10 VPC displays a unique profile of secretion factors involved in vascular growth, muscle regeneration, matrix remodeling, and anticoagulation. In particular, D10 VPC secretes more factors involved in vascular growth (e.g., CCL2, ANGPT1, ANGPT2, SDFla), muscle regeneration e.g., HGF), and wound repair / matrix remodeling (e.g., EGF, ANGPTL4) than D6 VPC.Example 5. In Vitro Assay - Tube Stabilization.
[0267] D10 VPC were further tested in vitro for their ability to stabilize vascular tube formation. GFP-HUVEC were seeded onto reduced growth factor Matrigel at 50K / well in a 24- well plate (21K / cm2) in Complete Vasculife media and incubated in normoxia overnight. The next day, wells were imaged to collect baseline of GFP-HUVEC tube formation. After imaging, 50K VPC were overlaid onto the network in depleted Vasculife media (without FBS, VEGF, or FGF2) and incubated under hypoxic conditions (1% O2). End-point analysis47MEI 52993232v.l127206-11520occurred on Day 7, whereby wells were imaged and assessed in automated, blinded fashion using the Wimasis software. See FIG. 7A. Percentages of EC covered area, total tube length, total tube numbers, and total branch points were assessed.
[0268] As shown in FIG. 7B, DIO VPC was able to both stabilize and enhance tube formation under both hypoxic and serum- starved conditions in vitro. DIO VPC performed better than D6 VPC in almost all readouts, particularly in branch points.Example 6. In Vivo Assay in a Diabetic Therapeutic Model
[0269] The efficacy of DIO VPC was evaluated in a diabetic therapeutic animal model. Briefly, db / db mice were subjected to the surgery to induce hindlimb ischemia (HLI) on Day 0. The hindlimb ischemia mouse model is a commonly used preclinical model for peripheral arterial disease, critical limb ischemia, intermittent claudication, Buerger's disease, acute limb ischemia, acute lung injury, and acute respiratory distress syndrome (ARDS) (Aref, et al., Int J Mol Sci. 2019 Jul 29;20(15):3704; Ribieras, et al., TherAdv Rare Dis. 2022 Jan 30: 3: 26330040211070295; Aeffner, et al., Toxicologic Pathology. 2015;43(8): 1074- 109). A dose of IxlO6D10 VPC or D6 VPC was injected into the mice on Day 21. Blood flow in the diabetic mice was monitored over the course of the experiment through Day 84 post surgery and capillary density in ischemic tissues was assessed on Day 84 post surgery. As shown in FIGS. 8A and 8B, D10 VPC shows a better efficacy in improving blood flow and increasing capillary density than D6 VPC.
[0270] Further experiments were performed to evaluate the effect of multiple injection sites on the efficacy of D10 VPC, and to determine the minimal effective dose for D10 VPC in db / db mice.
[0271] A dose of about IxlO6D10 VPC was divided among either 2 injection sites or 4 injection sites along the length of the limb of db / db mice with hind limb ischemia on Day 21. The dose per injection site is about 0.5xl06D10 VPC for the group of mice receiving 2 injections (n=10). The dose per injection site is about 0.25xl06D10 VPC for the group of mice receiving 4 injections (n-14). Two lots of D10 VPC were tested in this experiment (Lot #1 and Lot #2). Blood flow in the diabetic mice was monitored over the course of the experiment. As shown in FIG. 8C, distribution of a dose of IxlO6D10 VPC over multiple injection sites exhibited comparable efficacy in improving blood flow versus vehicle control. None of the cell treated groups (2 injection vs 4 injections or Lot #1 vs Lot #2) are statistically significant when compared to each other.48MEI 52993232v.l127206-11520
[0272] Next, a dose reponse study was performed to evaluate the minimal effective dose of DIO VPC in diabetic mice, db / db mice with ischemia were injected with a total dose of 0.05xl06, O.lxlO6, 0.25xl06, or IxlO6DIO VPC at 4 injection sites on D21. Two lots of DIO VPC were tested in this experiment (Lot #1 and Lot #2). Blood flow in the diabetic mice was monitored over the course of the experiment. As shown in FIG.8D, all doses were able to significantly improve the blood flow when compared to the vehicle control after Day 36. Both DIO VPC lots improved blood flow in a dose-dependent manner and this dosedependency appears to increase over time.Example 7. Deliberate Series of Required Steps to Achieve the Unique Profile of DIO VPC
[0273] As described in Example 1, the method herein for generating VPC includes steps of harvesting, freezing and thawing intermediate VPC cells on Day 6 (D6 VPCs), and subsequently replating the thawed D6 VPCs in an endothelial expansion medium. The following
[0274] Additional experiments were performed to test whether the steps of harvesting, freezing, thawing and / or replating are required to achieve the unique profile of Day 10 VPCs. These experiments showed that each of the steps are important to generate functional D10 VPCs with a good safety profile (data not included).
[0275] Taken together, these data demonstrate that the method described in Example 1 contains steps and reagents that are required for generating D10 VPCs with unique phenotypes and functionality. Said method as well as the unique D10 VPCs generated therefrom are not a “natural phenomenon”. Instead, this is a unique, distinct finding resulting from understanding of the mechanistic signaling and biological impact of applied process changes.Example 8. D10 VPC Can be Passaged and Maintain Similar Phenotype
[0276] D10 VPCs were differentiated and cultured as described in Example 1, except that at Day 10, instead of collecting the cells, D10 VPCs were passaged at similar seeding density (28K / cm2) and cultured for an additional four days at 5% O2 in the same endothelial expansion medium (StemDiff + heparin + hydrocortisone) with one full media change on Day 12. Day 14 cells were harvested with TrypLE and frozen for future analysis. Flow cytometry on these cells indicates largely similar phenotype as the D10 VPC, except minor49MEI 52993232v.l127206-11520decreases in CD34 and CD43 expression (FIG. 12). In contrast, there are large differences in phenotype between D6 and D10 / D14 VPC, particularly in CD34, CD43, CXCR4, CD271, PDPN, CD34+CD144+, CD 140b, and CD43+CD144+ expression, further confirming that D6 VPC to DIO VPC is not a simple passaging of cells, but further differentiation. However, once this additional differentiation is obtained (i.e., DIO VPC), these DIO VPC can be passaged at least once and maintain a broadly similar phenotype.Equivalents
[0277] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein, such equivalents are intended to be encompassed by the following claims. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.MEI 52993232v.l
Claims
127206-11520CLAIMSWhat is claimed is:
1. A method for producing a population of vascular progenitor cells (VPCs) by in vitro differentiation of pluripotent stem cells, wherein the method comprises(a) culturing the pluripotent stem cells on an extracellular matrix surface in a pluripotent stem cell expansion medium,(b) culturing the pluripotent stem cells from step (a) on an extracellular matrix surface in a VPC differentiation medium comprising vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and bone morphogenetic protein 4 (BMP4) for about 6 days to produce a population of intermediate VPCs,(c) harvesting the population of intermediate VPCs from step (b); and(d) replating the population of intermediate VPCs from step (c) on an extracellular matrix surface in an endothelial expansion medium for about 4 or more days, thereby producing the population of VPCs.
2. The method of claim 1, wherein the extracellular matrix surface is a collagen-IV-coated surface.
3. The method of claim 1 or 2, wherein the extracellular matrix surface is a human collagen-IV-coated surface.
4. The method of claim 1 or 2, wherein the pluripotent stem cells are human embryonic stem cells, or human induced pluripotent stem cells.
5. The method of any one of claims 1-4, wherein the pluripotent stem cell expansion medium comprises a Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor.
6. The method of any one of claims 1-5, wherein the pluripotent stem cell expansion medium comprises about 5-20 pM ROCK inhibitor.
7. The method of any one of claims 1-6, wherein the pluripotent stem cell expansion medium comprises about 10 M ROCK inhibitor.
8. The method of any one of claims 1-7, wherein the ROCK inhibitor is Y27632.
9. The method of any one of claims 1-8, wherein the VPC differentiation medium comprises about 5-50 ng / mL VEGF, about 5-50 ng / mL FGF, and about 5-25 ng / mL BMP4.51MEI 52993232v.l127206-1152010. The method of any one of claims 1-9, wherein the VPC differentiation medium comprises about 50 ng / mL VEGF, about 50 ng / mL FGF, and about 25 ng / mL BMP4.
11. The method of any one of claims 1-10, wherein the endothelial expansion medium comprises heparin and hydrocortisone.
12. The method of any one of claims 1-11, wherein the endothelial expansion medium comprises about 5-50 pg / mL heparin, and about 0.1-10 pg / mL hydrocortisone.
13. The method of any one of claims 1-12, wherein the endothelial expansion medium comprises about 12 pg / mL heparin, and about 1 pg / mL hydrocortisone.
14. The method of any one of claims 1-13, wherein the endothelial expansion medium further comprises a ROCK inhibitor, a TGFp inhibitor, a Notch signaling inhibitor, and / or Forskolin.
15. The method of any one of claims 1-13, wherein the endothelial expansion medium further comprises about 5-20 pM ROCK inhibitor, about 5-20 pM TGFp inhibitor, about 5-20 pM Notch signaling inhibitor, and / or about 5-20 pM Forskolin.
16. The method of any one of claims 1-13, wherein the endothelial expansion medium further comprises about 10 pM ROCK inhibitor and / or about 10 pM TGFp inhibitor.
17. The method of any one of claims 1-13, wherein the endothelial expansion medium further comprises about 5 pM Forskolin, about 5 pM Notch signaling inhibitor, and / or about 5 pM TGFP inhibitor.
18. The method of any one of claims 14-16, (a) wherein the ROCK inhibitor is Y27632, (b) wherein the TGFp inhibitor is SB431542, and / or (c) wherein the Notch signaling inhibitor is DAPT.
19. The method of any one of claims 1-18, wherein the culturing in step (a) is performed for about 1 day.
20. The method of any one of claims 1-19, wherein the culturing in step (a) is conducted under a normoxia condition of 5% CO2 and 20% O2.
21. The method of any one of claims 1-20, wherein the culturing in step (b) is conducted under a hypoxia condition of 5% CO2 and 5% O2.
22. The method of any one of claims 1-21, wherein the culturing in step (d) is conducted under a hypoxia condition of 5% CO2 and 5% O2.52MEI 52993232v.l127206-1152023. The method of any one of claims 1-21, wherein the culturing in step (d) is conducted under a normoxia condition of 5% CO2 and 20% O2.
24. The method of any one of claims 1-23, wherein the pluripotent stem cells are cultured at a seeding density of about 2,500 to about 40,000 cells per cm2in step (a).
25. The method of any one of claims 1-24, wherein the pluripotent stem cells are cultured at a seeding density of about 5,000 to about 10,000 cells per cm2in step (a).
26. The method of any one of claims 1-25, wherein the population of intermediate VPCs are replated at a seeding density of about 28,000 to about 172,000 cells per cm2in step (d).
27. The method of any one of claims 1-26, further comprising freezing the population of intermediate VPCs from step (c).
28. The method of claim 27, wherein the population of intermediate VPCs are frozen for about 5 years or less.
29. The method of claim 27, wherein the population of intermediate VPCs are frozen for about 1 years or less.
30. The method of claim 27, wherein the population of intermediate VPCs are frozen for about 6 months or less.
31. The method of claim 27, wherein the population of intermediate VPCs are frozen for about 1 month or less.
32. The method of any one of claims 27-31, wherein the population of intermediate VPCs are frozen at a temperature of about -70°C or less.
33. The method of any one of claims 1-32, further comprising thawing the population of intermediate VPCs prior to replating in step (d).
34. The method of any one of claims 1-33, wherein the population of intermediate VPCs are replated in an endothelial expansion medium comprising heparin and hydrocortisone for about 4 or more days in step (d).
35. The method of any one of claims 1-33, wherein the population of intermediate VPCs are replated in an endothelial expansion medium comprising a ROCK inhibitor for about 2 or more days, and / or a TGFp inhibitor for about 4 or more days in step (d).53MEI 52993232v.l127206-1152036. The method of any one of claims 1-35, wherein the population of VPCs comprises about 30-80% CD31+CD144+ endothelial cells and about 20-70% CD140b+CD271+ MSC-like cells by flow cytometry.
37. The method of claim 36, wherein the endothelial cells are CD31+, CD144+ and CD271+.
38. The method of claim 36, wherein the endothelial cells are about 70-100% CD146+.
39. The method of claim 36, wherein the endothelial cells are about 60-90% CXCR4+.
40. The method of any one of claims 1-39, wherein the population of VPCs has an about 20-60% decrease in the expression by flow cytometry in one or more proteins selected from the group consisting of CD34 and CD43 as compared to the population of intermediate VPCs.
41. The method of any one of claims 1-40, wherein the population of VPCs comprises about 40-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells by single cell RN A- sequencing (scRNA-seq).
42. The method of any one of claims 1-41, wherein the population of VPCs comprises about 70-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells by scRNA-seq.
43. The method of any one of claims 1-42, wherein the population of VPCs comprises about 75-85% CD31+CD144+ endothelial cells and about 15-25% MEST+ALCAM+ MSC-like cells by scRNA-seq.
44. The method of any one of claims 1-43, wherein the population of VPCs comprises about 80% CD31+CD144+ endothelial cells and about 20% MEST+AECAM+ MSC-like cells by scRNA-seq.
45. The method of any one of claims 41-44, wherein the endothelial cells are CD31+, CD 144+ and CD271+.
46. The method of any one of claims 41-45, wherein the endothelial cells are not CD31 + , CD144- RUNX1+.54MEI 52993232v.l127206-1152047. The method of any one of claims 1-46, wherein the population of VPCs comprises less than about 1% EPCAM+S0X17+ endoderm-like cells by scRNA-seq.
48. The method of any one of claims 1-47, wherein the population of VPCs does not comprise OCT4+NANOG+SOX2 undifferentiated pluripotent stem cells by scRNA-seq.
49. The method of any one of claims 1-48, wherein the population of VPCs does not comprise OCT4+CDH2+ mesoderm cells by scRNA-seq.
50. The method of any one of claims 1-49, wherein the endothelial population of VPCs has an about 80-130% increase in the expression by scRNA-seq of one or more genes selected from the group consisting of CAV1, ANXA1, CD59, IGFBP3 and ANGPT2 as compared to the endothelial population of intermediate VPCs.
51. The method of any one of claims 1-50, wherein the endothelial population of VPCs has an about 25-75% decrease in the expression by scRNA-seq of one or more genes selected from the group consisting of APOE, CD24 and DLK1 as compared to the endothelial population of intermediate VPCs.
52. The method of any one of claims 1-51, wherein the endothelial population of VPCs has an about 20-50% decrease in the expression by scRNA-seq of one or more genes selected from the group consisting of CD34, RUNX1, CD44 and SPN as compared to the endothelial population of intermediate VPCs.
53. The method of any one of claims 1-52, wherein the endothelial population of VPCs has an about 40-90% increase in the expression by scRNA-seq of one or more genes selected from the group consisting of CXCR4, EFNB2, and GJA4 as compared to the endothelial population of intermediate VPCs.
54. The method of any one of claims 1-53, wherein the MSC-like population of VPCs has an about 30-60% decrease in the expression by scRNA-seq of one or more genes selected from the group consisting of ACTC1, BAMBI, HANDI, COL1A1, and COL1A2 as compared to the MSC-like population of intermediate VPCs.
55. The method of any one of claims 1-54, wherein the population of VPCs secrets an increased level of one or more proteins selected from the group consisting of CCL2, FGF2, ANGPT1, AGNPT2, SDFla, HGF, Follistatin, EGF, and ANGPTE4 as compared to the population of intermediate VPCs.55MEI 52993232v.l127206-1152056. A composition comprising a population of VPCs produced by the method of any one of claims 1-55.
57. A composition comprising a population of VPCs produced by in vitro differentiation of pluripotent stem cells, wherein the population of VPCs comprises about 40-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells by scRNA-seq.
58. A composition comprising a population of VPCs produced by in vitro differentiation of pluripotent stem cells, wherein the population of VPCs comprises about 70-90% CD31+CD144+ endothelial cells and about 10-30% MEST+ALCAM+ MSC-like cells by scRNA-seq .
59. The composition of any one of claims 56-58, wherein the population of VPCs comprises about 75-85% CD31+CD144+ endothelial cells and about 15-25% MEST+ALCAM+ MSC-like cells by scRNA-seq.
60. The composition of any one of claims 56-59, wherein the population of VPCs comprises about 80% CD31+CD144+ endothelial cells and about 20% MEST+ALCAM+ MSC-like cells by scRNA-seq.
61. The composition of any one of claims 56-60, wherein the endothelial cells are CD31+, CD 144+ and CD271+.
62. The composition of any one of claims 56-61, wherein the endothelial cells are not CD31 + , CD 144- and R UNXI + .
63. The composition of any one of claims 56-62, wherein the population of VPCs comprises less than about 1% EPCAM+SOX17+ endoderm-like cells by scRNA-seq.
64. The composition of any one of claims 56-63, wherein the population of VPCs does not comprise OCT4+NANOG+SOX2 undifferentiated pluripotent stem cells by scRNA-seq.
65. The composition of any one of claims 56-64, wherein the population of VPCs does not comprise OCT4+CDH2+ mesoderm cells by scRNA-seq.
66. The composition of any one of claims 56-65, wherein the endothelial population of VPCs has an about 80-130% increase in the expression by scRNA-seq of one or more genes selected from the group consisting of CAV1, ANXA1, CD59, IGFBP3 and ANGPT2 as compared to the endothelial population of intermediate VPCs.56MEI 52993232v.l127206-1152067. The composition of any one of claims 56-66, wherein the endothelial population of VPCs has an about 25-75% decrease in the expression by scRNA-seq of one or more genes selected from the group consisting of APOE, CD24 and DLK1 as compared to the endothelial population of intermediate VPCs.
68. The composition of any one of claims 56-67, wherein the endothelial population of VPCs has an about 20-50% decrease in the expression by scRNA-seq of one or more genes selected from the group consisting of CD34, RUNX1, CD44 and SPN as compared to the endothelial population of intermediate VPCs.
69. The composition of any one of claims 56-68, wherein the endothelial population of VPCs has an about 40-90% increase in the expression by scRNA-seq of one or more genes selected from the group consisting of CXCR4, EFNB2, and GJA4 as compared to the endothelial population of intermediate VPCs.
70. The composition of any one of claims 56-69, wherein the MSC-like population of VPCs has an about 30-60% decrease in the expression by scRNA-seq of one or more genes selected from the group consisting of ACTC1, BAMBI, HANDI, COL1A1, and COL1A2 as compared to the MSC-like population of intermediate VPCs.
71. The composition of any one of claims 56-70, wherein the population of VPCs secrets an increased level of one or more proteins selected from the group consisting of CCL2, FGF2, ANGPT1, AGNPT2, SDFla, HGF, Follistatin, EGF, and ANGPTE4 as compared to the population of intermediate VPCs.
72. A pharmaceutical composition comprising the composition of any one of claims 56-71, and a pharmaceutically acceptable carrier.
73. The pharmaceutical composition of claim 72, wherein the pharmaceutically acceptable carrier is a cryopreservation media.
74. The pharmaceutical composition of claim 72 or 73, wherein the pharmaceutically acceptable carrier is a cryopreservation media comprising about 5-10% DMSO.
75. The pharmaceutical composition of claim 72, wherein the pharmaceutically acceptable carrier is a biomaterial or a hydrogel.
76. The pharmaceutical composition of claim 72 or 75, wherein the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from hyaluronic acid, chitosan,57MEI 52993232v.l127206-11520collagen, elastin, fibrin, fibrinogen, gelatin, alginate, cellulose, silk, fibrin, polyacrylic acid (PAA), polyethylene glycol (PEG), polylactic-co-glycolic acid, and / or Pluronic F-127.
77. The pharmaceutical composition of claim 72 or 75, wherein the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from homogenously deacetylated chitin (HDC).
78. The pharmaceutical composition of claim 72 or 75, wherein the pharmaceutically acceptable carrier is a biomaterial or a hydrogel derived from crystalline cellulose / carmellose sodium (CMC-Na).
79. A method of treating a vascular disease in a subject in need thereof, comprising administering to the subject the composition of any one of claims 56-71, or the pharmaceutical composition of any one of claims 72-78, thereby treating the vascular disease in the subject.
80. The method of claim 79, wherein the administration of the composition or the pharmaceutical composition increases the blood flow, collateralization, arteriogenesis or capillary density in the subject.
81. The method of claim 79 or 80, wherein the administration of the composition or the pharmaceutical composition increases ankle-brachial index (AB I), increases tissue oxygenation, reduces ulcer / wound size, or promotes wound healing in the subject.
82. The method of any one of claims 79-81, wherein the administration of the composition or the pharmaceutical composition promotes the angiogenesis and / or vasculogenesis in the subject.
83. The method of any one of claims 79-82, wherein the administration of the composition or the pharmaceutical composition reduces the ischemic severity in the subject.
84. A method of increasing blood flow in a subject suffering from, or suspected of suffering from, a vascular disease, comprising administering to the subject the composition of any one of claims 56-71, or the pharmaceutical composition of any one of claims 72-78, thereby increasing the blood flow in the subject.
85. A method of increasing capillary density in a subject suffering from, or suspected of suffering from, a vascular disease, comprising administering to the subject the composition of any one of claims 56-71, or the pharmaceutical composition of any one of claims 72-78, thereby increasing the capillary density in the subject.58MEI 52993232v.l127206-1152086. A method of reducing blood pressure in a subject suffering from, or suspected of suffering from, a vascular disease, comprising administering to the subject the composition of any one of claims 56-71, or the pharmaceutical composition of any one of claims 72-78, thereby reducing the blood pressure in the subject.
87. A method of promoting wound healing in a subject suffering from, or suspected of suffering from, a vascular disease, comprising administering to the subject the composition of any one of claims 56-71, or the pharmaceutical composition of any one of claims 72-78, thereby promoting wound healing in the subject.
88. The method of any one of claims 79-87 wherein the vascular disease is selected from the group consisting of coronary artery diseases, arteriosclerosis, atherosclerosis, other diseases or injuries of the arteries, arterioles and capillaries or related complaint, myocardial infarction, acute myocardial infarction, organizing myocardial infarct, ischemic heart disease, arrhythmia, left ventricular dilatation, emboli, heart failure, congestive heart failure, subendocardial fibrosis, left or right ventricular hypertrophy, myocarditis, chronic coronary ischemia, dilated cardiomyopathy, restenosis, arrhythmia, angina, hypertension, pulmonary hypertension, glomerular hypertension, portal hypertension, myocardial hypertrophy, peripheral arterial disease, intermittent claudication, critical limb ischemia, diabetic foot ulcer, cerebrovascular disease, renal artery stenosis, aortic aneurysm, pulmonary heart disease, cardiac dysrhythmias, inflammatory heart disease, congenital heart disease, rheumatic heart disease, diabetic vascular diseases, diabetic retinopathy, Buerger's disease, Reynaud's syndrome, acute limb ischemia, endothelial lung injury diseases, acute lung injury (ALI), and acute respiratory distress syndrome (ARDS)).
89. The method of any one of claims 79-88, wherein the vascular disease is critical limb ischemia.
90. The method of any one of claims 79-88, wherein the vascular disease is diabetic vascular disease.
91. The method of any one of claims 79-88, wherein the vascular disease is peripheral arterial disease (PAD).
92. The method of any one of claims 79-88, wherein the vascular disease is intermittent claudication.59MEI 52993232v.l127206-1152093. The method of any one of claims 79-88, wherein the vascular disease is acute limb ischemia.
94. The method of any one of claims 79-88, wherein the vascular disease is Buerger’s disease.
95. The method of any one of claims 79-88, wherein the vascular disease is diabetic foot ulcer (DFU).
96. The method of any one of claims 79-88, wherein the vascular disease is acute respiratory distress syndrome (ARDS).
97. The method of any one of claims 79-88, wherein the vascular disease is acute lung injury (ALI).
98. The method of any one of claims 79-88, wherein the vascular disease is pulmonary arterial hypertension (PAH).
99. The method of any one of claims 79-88, wherein the vascular disease is diabetic retinopathy.
100. The method of any one of claims 79-99, wherein the composition or the pharmaceutical composition is administered locally or systemically.
101. The method of claim 100, wherein the composition or the pharmaceutical composition is administered at multiple injection sites.
102. The method of claim 100, wherein the composition or the pharmaceutical composition is administered at a dose of 0.05xl06, O.lxlO6, 0.25xl06, or IxlO6of the composition.
102. The method of any one of claims 79-99, wherein the composition or the pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, or intraocularly.
103. The method of any one of claims 79-99, wherein the composition or the pharmaceutical composition is administered peri-arterially.
104. The method of any one of claims 79-103, wherein the subject is a human subject.60MEI 52993232v.l
